Patent Application
20210246428
Pancreatic beta cells are regulators of blood glucose whose autoimmune destruction or dysfunction cause Type 1 and Type 2 diabetes. Recently, in vitro differentiation protocols have been developed that convert pluripotent stem cells into pancreatic beta cells1-3. For instance, the ‘SC-beta’ (stem cell-derived beta cells) protocol1 performs a stepwise differentiation using a combination of signaling cues derived from those that generate beta cells in vivo. The resulting stem-cell derived beta cells secrete insulin in response to glucose challenges and restore metabolic homeostasis in animal models of diabetes1. Consequently, in vitro differentiation protocols are leading candidates for the development of cell-based therapies for diabetes.
A challenge in producing any cell type in vitro is heterogeneity of the cells generated by directed differentiation. At each step of the process, some cells follow the desired path, others stray. To improve efficiency, it is important to identify all cell types produced during differentiation. High-throughput single-cell RNA sequencing4 characterizes cell types by unbiased transcriptional profiling of thousands of individual cells. Single-cell RNA sequencing has been applied to comprehensively characterize the cell types of many organs, including several studies of the adult human5-9 and embryonic mouse10,11 pancreas.
Previous studies with beta cell differentiation protocols have made a number of important observations. Co-expression of insulin and other key beta cell markers, combined with glucose-stimulated insulin secretion, constituted the primary proof that beta cells are indeed produced in vitro. Studies characterizing bulk gene expression profiles12,13 showed that transcriptional and epigenetic landscapes change for thousands of genes. Petersen et al.14 used single-cell qPCR to propose a model for in vitro pancreatic differentiation. None of these studies comprehensively determined the identities and states of all the cell types produced prior to and alongside in vitro beta cells.
In work described herein, single-cell RNA sequencing was used to identify and describe the cell types produced during in vitro differentiation of pluripotent stem cells to pancreatic beta cells. This analysis provides an unprecedented view of the sequence of transcriptional changes that underlie the formation of SC-beta cells and reveals fate-determinative decision points and alternative pathways that cells may follow along the differentiation road.
Among other aspects, this analysis has revealed that the SC-beta protocol produces stem cell-derived cells that closely resemble enterochromaffin cells (SC-EC cells). These SC-EC cells represent a distinct cell type produced alongside SC-beta cells. In vivo, enterochromaffin cells are epithelial endocrine cells that produce and secrete serotonin. Enterochromaffin cells and serotonin signaling may play a key role in the pathophysiology of several diseases, particularly those related to intestinal inflammation. Their transcriptional signature is described, as well as their ability to secrete serotonin when depolarized with KCl, demonstrating the creation of a novel human cell type in vitro. The invention relates in part to these non-naturally occurring SC-EC cells, which may serve as models for screening for drugs which may modify, or improve, serotonin signaling in the GI tract; they may also be used directly for cell replacement therapy.
In additional aspects, work described herein identifies markers for cell types produced by in vitro pancreatic beta cell differentiation. The single-cell RNA sequencing results provide a detailed characterization of the full transcriptomes of all cell populations produced during in vitro beta cell differentiation. Using this data, genes can be identified that are specifically enriched in single populations or combinations of populations. The knowledge that these genes are specific to a given population can be leveraged to further develop in vitro pancreatic beta cell differentiation methods, as well as methods for in vitro differentiation to other cell types (such as alpha cells).
More specifically, these genes can be used at least (i) as surface markers for antibody-based identification and/or enrichment of specific populations, and (ii) as targets for genetic perturbation (such as knock-out, activation or inhibition). This later aspect allows for creation of ‘tailored’ (non-wild type) stem cell lines that have been genetically edited to be incapable of mis-differentiating toward undesired fates. That is, by controlling the gene expression of cells during the differentiation process (at the pluripotent stage and/or at one or more later points in the differentiation process), one may open or close routes of differentiation, forcing a cell down a desired path or away from an undesired path.
Disclosed herein are stem cell-derived enterochromaffin cells (i.e., non-naturally occurring enterochromaffin cells).
In some embodiments, the cell expresses one or more of the following genes: TPH1, SLC18A1, LMX1A, PAX4, DDC, TRPA1, SCN3A, ADRa2A, FEV, TAC1, and CXCL14. In some embodiments, the cell co-expresses the genes TPH1, LMX1A, and SLC18A1. In some embodiments, the expression of the genes is enriched relative to in vivo pancreatic populations. In some embodiments, the cell does not express one or more of the following markers: G6PC2, NPTX2, ISL1, and PDX1.
In some embodiments, the cell is capable of producing serotonin (5-HT). In some embodiments, the cell releases serotonin in vitro upon depolarization with KCl and/or does not release serotonin in vitro upon stimulation with high glucose.
In some embodiments, the cell is differentiated in vitro from an endocrine cell, a pancreatic progenitor cell, or a pluripotent stem cell. In some aspects, the pancreatic progenitor cell is selected from the group consisting of a Pdx1+, NKX6-1+ pancreatic progenitor cell and a Pdx1+ pancreatic progenitor cell. In some aspects, the pluripotent stem cell is selected from the group consisting of an embryonic stem cell and induced pluripotent stem cell. In some embodiments, the pluripotent stem cell is a human cell.
Also disclosed herein are cell lines comprising the stem cell-derived enterochromaffin cells described herein. Also disclosed herein are SC-islets comprising one or more of the stem cell-derived enterochromaffin cells described herein.
Disclosed herein are methods of producing an SC-EC cell from a progenitor cell in vitro. The methods comprise contacting a population of cells comprising a pancreatic progenitor cell under conditions that promote cell clustering with at least six EC maturation factors comprising a) a TGF-β signaling pathway inhibitor, b) a thyroid hormone signaling pathway activator, c) a γ-secretase inhibitor, d) at least one growth factor from the EGF family, e) a retinoic acid (RA) signaling pathway activator, and f) a sonic hedgehog (SHH) pathway inhibitor to induce the differentiation of at least one pancreatic progenitor cell in the population into at least one SC-EC.
In some embodiments, the TGF-β signaling pathway inhibitor comprises Alk5 inhibitor II; the thyroid hormone signaling pathway activator comprises triiodothyronine (T3); the γ-secretase inhibitor comprises XXI; the at least one growth factor from the EGF family comprises betacellulin; the RA signaling pathway activator comprises RA; and/or the SHH pathway inhibitor comprises Sant1. In some embodiments, the population of cells is optionally contacted with a BMP signaling pathway inhibitor (e.g., LDN193189).
Also disclosed herein are methods of identifying cells (e.g., SC-β cells, SC-α cells, and/or SC-EC cells) in a population of endocrine cells. The methods comprise applying a diffusion pseudotime analysis to a population of endocrine cells; identifying one or more genes expressed by one or more cells within the population of endocrine cells; and identifying the one or more cells as SC-β cells, SC-α cells or SC-EC cells, wherein the SC-β cells express at least ISL1 and ERO1B, and wherein the SC-EC cells express at least TPH1 and LMX1A.
Also disclosed herein are methods of identifying SC-β cells within a population of endocrine cells. The methods comprises screening a population of endocrine cells for cells expressing at least ISL1 and ERO1B; and identifying cells within the population of endocrine cells as SC-β cells if they express at least ISL1 and ERO1B.
Disclosed herein are methods of identifying SC-EC cells within a population of endocrine cells. The methods comprise screening a population of endocrine cells for cells expressing at least TPH1 and LMX1A; and identifying cells within the population of endocrine cells as SC-EC cells if they express at least TPH1 and LMX1A.
Disclosed herein are methods for directing differentiation of a population of cells comprising modulating expression of a regulator of cell fate during a differentiation protocol, thereby directing differentiation of a population of cells towards a predetermined cell fate.
Also disclosed herein are methods for forming an enriched population of SC-β cells. The methods comprise applying anti-CD49a antibody and microbeads to a solution of dissociated cells; and isolating for cells enriched in CD49a, thereby forming an enriched population of SC-β cells.
Disclosed herein are methods for producing SC-islets comprising SC-β cells. The methods comprise obtaining Stage 6 clusters from a differentiation process; dissociating the Stage 6 clusters using a re-aggregation procedure; resuspending and staining dissociated single cells, wherein the cells are stained for CD49a; adding microbeads to a suspension of stained dissociated single cells; magnetically separating the single cells; and combining the separated single cells to form a cell population comprising an enriched yield of SC-β cells.
In some embodiments, the cells are stained for CD49a using anti-human CD49a antibody. In some embodiments, the cell population shows an enriched yield of 70% SC-β cells. In some embodiments, the cell population shows an enriched yield of 80% SC-β cells.
Also disclosed herein are methods for directing differentiation of a population of cells. The methods comprise inhibiting expression of a regulator of cell fate during a differentiation protocol, e.g., wherein the regulator is ARX, thereby directing differentiation of a population of cells toward SC-β cells.
Also disclosed herein are methods for directing differentiation of a population of cells. The methods comprise inhibiting expression of a first regulator of cell fate during a differentiation protocol, e.g., wherein the first regulator is ARX, and activating expression of a second regulator of cell fate during a differentiation protocol, e.g., wherein the second regulator is PAX4, thereby directing differentiation of a population of cells toward SC-β cells.
Disclosed herein are methods for directing differentiation of a population of cells comprising disrupting LMX1A during a differentiation protocol, thereby decreasing SC-EC production and directing differentiation of a population of cells towards SC-β cells. In some embodiments, the disruption of LMX1A occurs by knockdown using a gene editing technique. In some embodiments, the disruption of LMX1A occurs by knockout using a gene editing technique.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
TABLE A: provides a chart detailing the pseudotime regression analyses of Stage 6 SC-beta cells. The chart provides the results from the regression analysis of Stage 6 SC-beta pseudotime for all genes (see
TABLE B: provides a chart detailing the GSEA results for the pseudotime regression analyses of Stage 6 SC-beta cells (see
TABLE C: provides a chart detailing the pseudotime regression analyses of Stage 5, Day 0 progenitors. The chart provides the results from the regression analysis of Stage 5 populations gene expression for all genes (see
TABLE D: provides a chart detailing the pseudotime regression analyses of Stage 5, Day 1 progenitors. The chart provides the results from the regression analysis of Stage 5 populations gene expression for all genes (see
TABLE E: provides a chart detailing the pseudotime regression analyses of Stage 5, SC-beta and SC-EC branching. The chart provides the results from the regression analysis of Stage 5 populations gene expression for all genes (see
Aspects of the disclosure relate to alternative protocols for producing stem cell-derived beta cells (SC-β) cells. Other aspects of the disclosure relate to methods for identifying, distinguishing and enriching for cells contained within SC-β clusters, as well as methods of directing the differentiation of cells with multiple potential differentiation outcomes toward or away from particular differentiation outcomes. Still other aspects of the disclosure relate to stem cell-derived enterochromaffin (SC-EC) cells.
For convenience, certain terms employed herein, in the specification, examples and appended claims are collected here. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The term “differentiated cell” is meant any primary cell that is not, in its native form, pluripotent as that term is defined herein. Stated another way, the term “differentiated cell” refers to a cell of a more specialized cell type derived from a cell of a less specialized cell type (e.g., a stem cell such as an induced pluripotent stem cell) in a cellular differentiation process. Without wishing to be limited to theory, a pluripotent stem cell in the course of normal ontogeny can differentiate first to an endoderm cell that is capable of forming pancreas cells and other endoderm cell types. Further differentiation of an endoderm cell leads to the pancreatic pathway, where ˜98% of the cells become exocrine, ductular, or matrix cells, and ˜2% become endocrine cells.
As used herein, the term “somatic cell” refers to any cells forming the body of an organism, as opposed to germline cells. In mammals, germline cells (also known as “gametes”) are the spermatozoa and ova which fuse during fertilization to produce a cell called a zygote, from which the entire mammalian embryo develops. Every other cell type in the mammalian body—apart from the sperm and ova, the cells from which they are made (gametocytes) and undifferentiated stem cells—is a somatic cell: internal organs, skin, bones, blood, and connective tissue are all made up of somatic cells. In some embodiments the somatic cell is a “non-embryonic somatic cell”, by which is meant a somatic cell that is not present in or obtained from an embryo and does not result from proliferation of such a cell in vitro. In some embodiments the somatic cell is an “adult somatic cell”, by which is meant a cell that is present in or obtained from an organism other than an embryo or a fetus or results from proliferation of such a cell in vitro. Unless otherwise indicated the methods described herein can be performed both in vivo and in vitro.
As used herein, the term “adult cell” refers to a cell found throughout the body after embryonic development.
The term “endoderm cell” as used herein refers to a cell which is from one of the three primary germ cell layers in the very early embryo (the other two germ cell layers are the mesoderm and ectoderm). The endoderm is the innermost of the three layers. An endoderm cell differentiates to give rise first to the embryonic gut and then to the linings of respiratory and digestive tracts (e.g. the intestine), the liver and the pancreas.
The term “a cell of endoderm origin” as used herein refers to any cell which has developed or differentiated from an endoderm cell. For example, a cell of endoderm origin includes cells of the liver, lung, pancreas, thymus, intestine, stomach and thyroid. Without wishing to be bound by theory, liver and pancreas progenitors (also referred to as pancreatic progenitors) develop from endoderm cells in the embryonic foregut. Shortly after their specification, liver and pancreas progenitors rapidly acquire markedly different cellular functions and regenerative capacities. These changes are elicited by inductive signals and genetic regulatory factors that are highly conserved among vertebrates.
The term “pancreatic progenitor” or “pancreatic precursor” are used interchangeably herein and refer to a stem cell which is capable of forming any of pancreatic endocrine cells, pancreatic exocrine cells, or pancreatic duct cells. The term “Pdx1-positive pancreatic progenitor” or “Pdx1+ pancreatic progenitor” as used herein refers to a cell which is a pancreatic endoderm (PE) cell. A Pdx1-positive pancreatic progenitor expresses the marker Pdx1. Other markers include, but are not limited to Cdcp1, or Ptf1a, or HNF6 or NRx2.2. The expression of Pdx1 may be assessed by any method known by the skilled person such as immunochemistry using an anti-Pdx1 antibody or quantitative RT-PCR. The term “Pdx1-positive, NKX6-1-positive pancreatic progenitor” or “Pdx1+, NKX6-1+ pancreatic progenitor” as used herein refers to a cell which is a pancreatic endoderm (PE) cell. A Pdx1-positive, NKX6-1-positive pancreatic progenitor expresses the markers Pdx1 and NKX6-1. Other markers include, but are not limited to Cdcp1, or Ptf1a, or HNF6 or NRx2.2. The expression of NKX6-1 may be assessed by any method known by the skilled person such as immunochemistry using an anti-NKX6-1 antibody or quantitative RT-PCR.
The terms “stem cell-derived β cell”, “SC-β cell”, and “mature SC-β cell” refer to cells (e.g., pancreatic β cells) that display at least one marker indicative of a pancreatic β cell, express insulin, and display a GSIS response characteristic of an endogenous mature β cell. In some embodiments, the “SC-β cell” comprises a mature pancreatic β cell. It is to be understood that the SC-β cells need not be derived (e.g., directly) from stem cells, as the methods of the disclosure are capable of deriving SC-β cells from any insulin-positive endocrine cell or precursor thereof using any cell as a starting point (e.g., one can use embryonic stem cells, induced-pluripotent stem cells, progenitor cells, partially reprogrammed somatic cells (e.g., a somatic cell which has been partially reprogrammed to an intermediate state between an induced pluripotent stem cell and the somatic cell from which it was derived), multipotent cells, totipotent cells, a transdifferentiated version of any of the foregoing cells, etc, as the invention is not intended to be limited in this manner). Examples of SC-β cells, and methods of obtaining such SC-β cells, are described in WO 2015/002724 and WO 2014/201167, both of which are incorporated herein by reference in their entirety.
The term “exocrine cell” as used herein refers to a cell of an exocrine gland, i.e. a gland that discharges its secretion via a duct. In particular embodiments, an exocrine cell refers to a pancreatic exocrine cell, which is a pancreatic cell that produces enzymes that are secreted into the small intestine. These enzymes help digest food as it passes through the gastrointestinal tract. Pancreatic exocrine cells are also known as islets of Langerhans, that secrete two hormones, insulin and glucagon. The term “phenotype” refers to one or a number of total biological characteristics that define the cell or organism under a particular set of environmental conditions and factors, regardless of the actual genotype.
The term “pluripotent” as used herein refers to a cell with the capacity, under different conditions, to differentiate to more than one differentiated cell type, and preferably to differentiate to cell types characteristic of all three germ cell layers. Pluripotent cells are characterized primarily by their ability to differentiate to more than one cell type, preferably to all three germ layers, using, for example, a nude mouse teratoma formation assay. Pluripotency is also evidenced by the expression of embryonic stem (ES) cell markers, although the preferred test for pluripotency is the demonstration of the capacity to differentiate into cells of each of the three germ layers. It should be noted that simply culturing such cells does not, on its own, render them pluripotent. Reprogrammed pluripotent cells (e.g. iPS cells as that term is defined herein) also have the characteristic of the capacity of extended passaging without loss of growth potential, relative to primary cell parents, which generally have capacity for only a limited number of divisions in culture.
As used herein, the terms “iPS cell” and “induced pluripotent stem cell” are used interchangeably and refers to a pluripotent stem cell artificially derived (e.g., induced or by complete reversal) from a non-pluripotent cell, typically an adult somatic cell, for example, by inducing a forced expression of one or more genes.
The term “progenitor” or “precursor” cell are used interchangeably herein and refer to cells that have a cellular phenotype that is more primitive (i.e., is at an earlier step along a developmental pathway or progression than is a fully differentiated cell) relative to a cell which it can give rise to by differentiation. Often, progenitor cells also have significant or very high proliferative potential. Progenitor cells can give rise to multiple distinct differentiated cell types or to a single differentiated cell type, depending on the developmental pathway and on the environment in which the cells develop and differentiate.
The term “stem cell” as used herein, refers to an undifferentiated cell which is capable of proliferation and giving rise to more progenitor cells having the ability to generate a large number of mother cells that can in turn give rise to differentiated, or differentiable daughter cells. The daughter cells themselves can be induced to proliferate and produce progeny that subsequently differentiate into one or more mature cell types, while also retaining one or more cells with parental developmental potential. The term “stem cell” refers to a subset of progenitors that have the capacity or potential, under particular circumstances, to differentiate to a more specialized or differentiated phenotype, and which retains the capacity, under certain circumstances, to proliferate without substantially differentiating. In one embodiment, the term stem cell refers generally to a naturally occurring mother cell whose descendants (progeny) specialize, often in different directions, by differentiation, e.g., by acquiring completely individual characters, as occurs in progressive diversification of embryonic cells and tissues. Cellular differentiation is a complex process typically occurring through many cell divisions. A differentiated cell may derive from a multipotent cell which itself is derived from a multipotent cell, and so on. While each of these multipotent cells may be considered stem cells, the range of cell types each can give rise to may vary considerably. Some differentiated cells also have the capacity to give rise to cells of greater developmental potential. Such capacity may be natural or may be induced artificially upon treatment with various factors. In many biological instances, stem cells are also “multipotent” because they can produce progeny of more than one distinct cell type, but this is not required for “stem-ness.” Self-renewal is the other classical part of the stem cell definition, and it is essential as used in this document. In theory, self-renewal can occur by either of two major mechanisms. Stem cells may divide asymmetrically, with one daughter retaining the stem state and the other daughter expressing some distinct other specific function and phenotype. Alternatively, some of the stem cells in a population can divide symmetrically into two stems, thus maintaining some stem cells in the population as a whole, while other cells in the population give rise to differentiated progeny only. Formally, it is possible that cells that begin as stem cells might proceed toward a differentiated phenotype, but then “reverse” and re-express the stem cell phenotype, a term often referred to as “dedifferentiation” or “reprogramming” or “retrodifferentiation” by persons of ordinary skill in the art. As used herein, the term “pluripotent stem cell” includes embryonic stem cells, induced pluripotent stem cells, placental stem cells, etc.
In the context of cell ontogeny, the adjective “differentiated”, or “differentiating” is a relative term meaning a “differentiated cell” is a cell that has progressed further down the developmental pathway than the cell it is being compared with. Thus, stem cells can differentiate to lineage-restricted precursor cells (such as a mesodermal stem cell), which in turn can differentiate into other types of precursor cells further down the pathway (such as a cardiomyocyte precursor), and then to an end-stage differentiated cell, which plays a characteristic role in a certain tissue type, and may or may not retain the capacity to proliferate further.
The term “embryonic stem cell” is used to refer to the pluripotent stem cells of the inner cell mass of the embryonic blastocyst (see U.S. Pat. Nos. 5,843,780, 6,200,806). Such cells can similarly be obtained from the inner cell mass of blastocysts derived from somatic cell nuclear transfer (see, for example, U.S. Pat. Nos. 5,945,577, 5,994,619, 6,235,970). The distinguishing characteristics of an embryonic stem cell define an embryonic stem cell phenotype. Accordingly, a cell has the phenotype of an embryonic stem cell if it possesses one or more of the unique characteristics of an embryonic stem cell such that that cell can be distinguished from other cells. Exemplary distinguishing embryonic stem cell characteristics include, without limitation, gene expression profile, proliferative capacity, differentiation capacity, karyotype, responsiveness to particular culture conditions, and the like.
The term “adult stem cell” or “ASC” is used to refer to any multipotent stem cell derived from non-embryonic tissue, including fetal, juvenile, and adult tissue. Stem cells have been isolated from a wide variety of adult tissues including blood, bone marrow, brain, olfactory epithelium, skin, pancreas, skeletal muscle, and cardiac muscle. Each of these stem cells can be characterized based on gene expression, factor responsiveness, and morphology in culture. Exemplary adult stem cells include neural stem cells, neural crest stem cells, mesenchymal stem cells, hematopoietic stem cells, and pancreatic stem cells. As indicated above, stem cells have been found resident in virtually every tissue. Accordingly, the present invention appreciates that stem cell populations can be isolated from virtually any animal tissue.
The term “reprogramming” as used herein refers to the process that alters or reverses the differentiation state of a somatic cell. The cell can either be partially or terminally differentiated prior to the reprogramming. Reprogramming encompasses complete reversion of the differentiation state of a somatic cell to a pluripotent cell. Such complete reversal of differentiation produces an induced pluripotent (iPS) cell. Reprogramming as used herein also encompasses partial reversion of a cells differentiation state, for example to a multipotent state or to a somatic cell that is neither pluripotent or multipotent, but is a cell that has lost one or more specific characteristics of the differentiated cell from which it arises, e.g. direct reprogramming of a differentiated cell to a different somatic cell type. Reprogramming generally involves alteration, e.g., reversal, of at least some of the heritable patterns of nucleic acid modification (e.g., methylation), chromatin condensation, epigenetic changes, genomic imprinting, etc., that occur during cellular differentiation as a zygote develops into an adult.
The term “agent” as used herein means any compound or substance such as, but not limited to, a small molecule, nucleic acid, polypeptide, peptide, drug, ion, etc. An “agent” can be any chemical, entity or moiety, including without limitation synthetic and naturally-occurring proteinaceous and non-proteinaceous entities. In some embodiments, an agent is nucleic acid, nucleic acid analogues, proteins, antibodies, peptides, aptamers, oligomer of nucleic acids, amino acids, or carbohydrates including without limitation proteins, oligonucleotides, ribozymes, DNAzymes, glycoproteins, siRNAs, lipoproteins, aptamers, and modifications and combinations thereof etc. In certain embodiments, agents are small molecule having a chemical moiety. For example, chemical moieties included unsubstituted or substituted alkyl, aromatic, or heterocyclyl moieties including macrolides, leptomycins and related natural products or analogues thereof. Compounds can be known to have a desired activity and/or property, or can be selected from a library of diverse compounds.
As used herein, the term “contacting” (i.e., contacting at least one endocrine cell or a precursor thereof with a maturation factor, or combination of maturation factors) is intended to include incubating the maturation factor and the cell together in vitro (e.g., adding the maturation factors to cells in culture). In some embodiments, the term “contacting” is not intended to include the in vivo exposure of cells to the compounds as disclosed herein that may occur naturally in a subject (i.e., exposure that may occur as a result of a natural physiological process). The step of contacting at least one endocrine cell or a precursor thereof with a maturation factor as in the embodiments described herein can be conducted in any suitable manner. For example, the cells may be treated in adherent culture, or in suspension culture. In some embodiments, the cells are treated in conditions that promote cell clustering. The disclosure contemplates any conditions which promote cell clustering. Examples of conditions that promote cell clustering include, without limitation, suspension culture in low attachment tissue culture plates, spinner flasks, or aggrewell plates. In some embodiments, the inventors have observed that clusters have remained stable in media containing 10% serum. In some embodiments, the conditions that promote clustering include a low serum medium.
It is understood that the cells contacted with a maturation factor can also be simultaneously or subsequently contacted with another agent, such as a growth factor or other differentiation agent or environments to stabilize the cells, or to differentiate the cells further.
The term “cell culture medium” (also referred to herein as a “culture medium” or “medium”) as referred to herein is a medium for culturing cells containing nutrients that maintain cell viability and support proliferation. The cell culture medium may contain any of the following in an appropriate combination: salt(s), buffer(s), amino acids, glucose or other sugar(s), antibiotics, serum or serum replacement, and other components such as peptide growth factors, etc. Cell culture media ordinarily used for particular cell types are known to those skilled in the art.
The term “cell line” refers to a population of largely or substantially identical cells that has typically been derived from a single ancestor cell or from a defined and/or substantially identical population of ancestor cells. The cell line may have been or may be capable of being maintained in culture for an extended period (e.g., months, years, for an unlimited period of time). It may have undergone a spontaneous or induced process of transformation conferring an unlimited culture lifespan on the cells. Cell lines include all those cell lines recognized in the art as such. It will be appreciated that cells acquire mutations and possibly epigenetic changes over time such that at least some properties of individual cells of a cell line may differ with respect to each other. In some embodiments, a cell line comprises a stem cell derived cell described herein.
The term “exogenous” refers to a substance present in a cell or organism other than its native source. For example, the terms “exogenous nucleic acid” or “exogenous protein” refer to a nucleic acid or protein that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is not normally found or in which it is found in lower amounts. A substance will be considered exogenous if it is introduced into a cell or an ancestor of the cell that inherits the substance. In contrast, the term “endogenous” refers to a substance that is native to the biological system.
The term “expression” refers to the cellular processes involved in producing RNA and proteins and as appropriate, secreting proteins, including where applicable, but not limited to, for example, transcription, translation, folding, modification and processing. “Expression products” include RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene.
The terms “genetically modified” or “engineered” cell as used herein refers to a cell into which an exogenous nucleic acid has been introduced by a process involving the hand of man (or a descendant of such a cell that has inherited at least a portion of the nucleic acid). The nucleic acid may for example contain a sequence that is exogenous to the cell, it may contain native sequences (i.e., sequences naturally found in the cells) but in a non-naturally occurring arrangement (e.g., a coding region linked to a promoter from a different gene), or altered versions of native sequences, etc. The process of transferring the nucleic acid into the cell can be achieved by any suitable technique. Suitable techniques include calcium phosphate or lipid-mediated transfection, electroporation, and transduction or infection using a viral vector. In some embodiments the polynucleotide or a portion thereof is integrated into the genome of the cell. The nucleic acid may have subsequently been removed or excised from the genome, provided that such removal or excision results in a detectable alteration in the cell relative to an unmodified but otherwise equivalent cell. It should be appreciated that the term genetically modified is intended to include the introduction of a modified RNA directly into a cell (e.g., a synthetic, modified RNA). Such synthetic modified RNAs include modifications to prevent rapid degradation by endo- and exo-nucleases and to avoid or reduce the cell's innate immune or interferon response to the RNA. Modifications include, but are not limited to, for example, (a) end modifications, e.g., 5′ end modifications (phosphorylation dephosphorylation, conjugation, inverted linkages, etc.), 3′ end modifications (conjugation, DNA nucleotides, inverted linkages, etc.), (b) base modifications, e.g., replacement with modified bases, stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, or conjugated bases, (c) sugar modifications (e.g., at the 2′ position or 4′ position) or replacement of the sugar, as well as (d) internucleoside linkage modifications, including modification or replacement of the phosphodiester linkages. To the extent that such modifications interfere with translation (i.e., results in a reduction of 50% or more in translation relative to the lack of the modification—e.g., in a rabbit reticulocyte in vitro translation assay), the modification is not suitable for the methods and compositions described herein.
The term “identity” as used herein refers to the extent to which the sequence of two or more nucleic acids or polypeptides is the same. The percent identity between a sequence of interest and a second sequence over a window of evaluation, e.g., over the length of the sequence of interest, may be computed by aligning the sequences, determining the number of residues (nucleotides or amino acids) within the window of evaluation that are opposite an identical residue allowing the introduction of gaps to maximize identity, dividing by the total number of residues of the sequence of interest or the second sequence (whichever is greater) that fall within the window, and multiplying by 100. When computing the number of identical residues needed to achieve a particular percent identity, fractions are to be rounded to the nearest whole number. Percent identity can be calculated with the use of a variety of computer programs known in the art. For example, computer programs such as BLAST2, BLASTN, BLASTP, Gapped BLAST, etc., generate alignments and provide percent identity between sequences of interest. The algorithm of Karlin and Altschul (Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:22264-2268, 1990) modified as in Karlin and Altschul, Proc. Natl. Acad. ScL USA 90:5873-5877, 1993 is incorporated into the NBLAST and XBLAST programs of Altschul et al. (Altschul, et al., J. MoI. Biol. 215:403-410, 1990). To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described in Altschul et al. (Altschul, et al. Nucleic Acids Res. 25: 3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs may be used. A PAM250 or BLOSUM62 matrix may be used. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (NCBI). See the Web site having URL world-wide web address of: “ncbi.nlm nih.gov” for these programs. In a specific embodiment, percent identity is calculated using BLAST2 with default parameters as provided by the NCBI.
The term “isolated” or “partially purified” as used herein refers, in the case of a nucleic acid or polypeptide, to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) that is present with the nucleic acid or polypeptide as found in its natural source and/or that would be present with the nucleic acid or polypeptide when expressed by a cell, or secreted in the case of secreted polypeptides. A chemically synthesized nucleic acid or polypeptide or one synthesized using in vitro transcription/translation is considered “isolated”. The term “isolated cell” as used herein refers to a cell that has been removed from an organism in which it was originally found or a descendant of such a cell. Optionally the cell has been cultured in vitro, e.g., in the presence of other cells. Optionally the cell is later introduced into a second organism or re-introduced into the organism from which it (or the cell from which it is descended) was isolated.
The term “isolated population” with respect to an isolated population of cells as used herein refers to a population of cells that has been removed and separated from a mixed or heterogeneous population of cells. In some embodiments, an isolated population is a substantially pure population of cells as compared to the heterogeneous population from which the cells were isolated or enriched from.
The term “substantially pure”, with respect to a particular cell population, refers to a population of cells that is at least about 75%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% pure, with respect to the cells making up a total cell population.
The terms “enriching” or “enriched” are used interchangeably herein and mean that the yield (fraction) of cells of one type is increased by at least 10% over the fraction of cells of that type in the starting culture or preparation.
The terms “renewal” or “self-renewal” or “proliferation” are used interchangeably herein, and are used to refer to the ability of stem cells to renew themselves by dividing into the same non-specialized cell type over long periods, and/or many months to years. In some instances, proliferation refers to the expansion of cells by the repeated division of single cells into two identical daughter cells.
The term “lineages” as used herein describes a cell with a common ancestry or cells with a common developmental fate. For example, in the context of a cell that is of endoderm origin or is “endodermal linage” this means the cell was derived from an endoderm cell and can differentiate along the endoderm lineage restricted pathways, such as one or more developmental lineage pathways which give rise to definitive endoderm cells, which in turn can differentiate into liver cells, thymus, pancreas, lung and intestine.
As used herein, the term “xenogeneic” refers to cells that are derived from different species.
A “marker” as used herein is used to describe the characteristics and/or phenotype of a cell. Markers can be used for selection of cells comprising characteristics of interests. Markers will vary with specific cells. Markers are characteristics, whether morphological, functional or biochemical (enzymatic) characteristics of the cell of a particular cell type, or molecules expressed by the cell type. Preferably, such markers are proteins, and more preferably, possess an epitope for antibodies or other binding molecules available in the art. However, a marker may consist of any molecule found in a cell including, but not limited to, proteins (peptides and polypeptides), lipids, polysaccharides, nucleic acids and steroids. Examples of morphological characteristics or traits include, but are not limited to, shape, size, and nuclear to cytoplasmic ratio. Examples of functional characteristics or traits include, but are not limited to, the ability to adhere to particular substrates, ability to incorporate or exclude particular dyes, ability to migrate under particular conditions, and the ability to differentiate along particular lineages. Markers may be detected by any method available to one of skill in the art. Markers can also be the absence of a morphological characteristic or absence of proteins, lipids etc. Markers can be a combination of a panel of unique characteristics of the presence and absence of polypeptides and other morphological characteristics.
The term “modulate” is used consistently with its use in the art, i.e., meaning to cause or facilitate a qualitative or quantitative change, alteration, or modification in a process, pathway, or phenomenon of interest. Without limitation, such change may be an increase, decrease, or change in relative strength or activity of different components or branches of the process, pathway, or phenomenon. A “modulator” is an agent that causes or facilitates a qualitative or quantitative change, alteration, or modification in a process, pathway, or phenomenon of interest.
As used herein, the term “DNA” is defined as deoxyribonucleic acid.
The term “polynucleotide” is used herein interchangeably with “nucleic acid” to indicate a polymer of nucleosides. Typically a polynucleotide of this invention is composed of nucleosides that are naturally found in DNA or RNA (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) joined by phosphodiester bonds. However the term encompasses molecules comprising nucleosides or nucleoside analogs containing chemically or biologically modified bases, modified backbones, etc., whether or not found in naturally occurring nucleic acids, and such molecules may be preferred for certain applications. Where this application refers to a polynucleotide it is understood that both DNA, RNA, and in each case both single- and double-stranded forms (and complements of each single-stranded molecule) are provided. “Polynucleotide sequence” as used herein can refer to the polynucleotide material itself and/or to the sequence information (i.e. the succession of letters used as abbreviations for bases) that biochemically characterizes a specific nucleic acid. A polynucleotide sequence presented herein is presented in a 5′ to 3′ direction unless otherwise indicated.
The terms “polypeptide” as used herein refers to a polymer of amino acids. The terms “protein” and “polypeptide” are used interchangeably herein. A peptide is a relatively short polypeptide, typically between about 2 and 60 amino acids in length. Polypeptides used herein typically contain amino acids such as the 20 L-amino acids that are most commonly found in proteins. However, other amino acids and/or amino acid analogs known in the art can be used. One or more of the amino acids in a polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a fatty acid group, a linker for conjugation, functionalization, etc. A polypeptide that has a non-polypeptide moiety covalently or non-covalently associated therewith is still considered a “polypeptide”. Exemplary modifications include glycosylation and palmitoylation. Polypeptides may be purified from natural sources, produced using recombinant DNA technology, synthesized through chemical means such as conventional solid phase peptide synthesis, etc. The term “polypeptide sequence” or “amino acid sequence” as used herein can refer to the polypeptide material itself and/or to the sequence information (i.e., the succession of letters or three letter codes used as abbreviations for amino acid names) that biochemically characterizes a polypeptide. A polypeptide sequence presented herein is presented in an N-terminal to C-terminal direction unless otherwise indicated.
The term a “variant” in referring to a polypeptide could be, e.g., a polypeptide at least 80%, 85%, 90%, 95%, 98%, or 99% identical to full length polypeptide. The variant could be a fragment of full length polypeptide. The variant could be a naturally occurring splice variant. The variant could be a polypeptide at least 80%, 85%, 90%, 95%, 98%, or 99% identical to a fragment of the polypeptide, wherein the fragment is at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, or 99% as long as the full length wild type polypeptide or a domain thereof having an activity of interest. In some embodiments the domain is at least 100, 200, 300, or 400 amino acids in length, beginning at any amino acid position in the sequence and extending toward the C-terminus. Variations known in the art to eliminate or substantially reduce the activity of the protein are preferably avoided. In some embodiments, the variant lacks an N- and/or C-terminal portion of the full length polypeptide, e.g., up to 10, 20, or 50 amino acids from either terminus is lacking. In some embodiments the polypeptide has the sequence of a mature (full length) polypeptide, by which is meant a polypeptide that has had one or more portions such as a signal peptide removed during normal intracellular proteolytic processing (e.g., during co-translational or post-translational processing). In some embodiments wherein the protein is produced other than by purifying it from cells that naturally express it, the protein is a chimeric polypeptide, by which is meant that it contains portions from two or more different species. In some embodiments wherein a protein is produced other than by purifying it from cells that naturally express it, the protein is a derivative, by which is meant that the protein comprises additional sequences not related to the protein so long as those sequences do not substantially reduce the biological activity of the protein.
The term “functional fragments” as used herein is a polypeptide having an amino acid sequence which is smaller in size than, but substantially homologous to the polypeptide it is a fragment of, and where the functional fragment polypeptide sequence is about at least 50%, or 60% or 70% or 80% or 90% or 100% or greater than 100%, for example 1.5-fold, 2-fold, 3-fold, 4-fold or greater than 4-fold effective biological action as the polypeptide from which it is a fragment of. Functional fragment polypeptides may have additional functions that can include decreased antigenicity, increased DNA binding (as in transcription factors), or altered RNA binding (as in regulating RNA stability or degradation).
The term “vector” refers to a carrier DNA molecule into which a DNA sequence can be inserted for introduction into a host cell. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors”. Thus, an “expression vector” is a specialized vector that contains the necessary regulatory regions needed for expression of a gene of interest in a host cell. In some embodiments the gene of interest is operably linked to another sequence in the vector. Vectors can be viral vectors or non-viral vectors. Should viral vectors be used, it is preferred the viral vectors are replication defective, which can be achieved for example by removing all viral nucleic acids that encode for replication. A replication defective viral vector will still retain its infective properties and enters the cells in a similar manner as a replicating adenoviral vector, however once admitted to the cell a replication defective viral vector does not reproduce or multiply. Vectors also encompass liposomes and nanoparticles and other means to deliver DNA molecule to a cell.
The term “operably linked” means that the regulatory sequences necessary for expression of the coding sequence are placed in the DNA molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement of coding sequences and transcription control elements (e.g. promoters, enhancers, and termination elements) in an expression vector. The term “operatively linked” includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed, and maintaining the correct reading frame to permit expression of the polynucleotide sequence under the control of the expression control sequence, and production of the desired polypeptide encoded by the polynucleotide sequence.
The term “viral vectors” refers to the use of viruses, or virus-associated vectors as carriers of a nucleic acid construct into a cell. Constructs may be integrated and packaged into non-replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including retroviral and lentiviral vectors, for infection or transduction into cells. The vector may or may not be incorporated into the cell's genome. The constructs may include viral sequences for transfection, if desired. Alternatively, the construct may be incorporated into vectors capable of episomal replication, e.g EPV and EBV vectors.
The terms “regulatory sequence” and “promoter” are used interchangeably herein, and refer to nucleic acid sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operatively linked. In some examples, transcription of a recombinant gene is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally-occurring form of a protein. In some instances the promoter sequence is recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required for initiating transcription of a specific gene.
As used herein, the term “transcription factor” refers to a protein that binds to specific parts of DNA using DNA binding domains and is part of the system that controls the transfer (or transcription) of genetic information from DNA to RNA. As used herein, “proliferating” and “proliferation” refer to an increase in the number of cells in a population (growth) by means of cell division. Cell proliferation is generally understood to result from the coordinated activation of multiple signal transduction pathways in response to the environment, including growth factors and other mitogens. Cell proliferation may also be promoted by release from the actions of intra- or extracellular signals and mechanisms that block or negatively affect cell proliferation.
The term “selectable marker” refers to a gene, RNA, or protein that when expressed, confers upon cells a selectable phenotype, such as resistance to a cytotoxic or cytostatic agent (e.g., antibiotic resistance), nutritional prototrophy, or expression of a particular protein that can be used as a basis to distinguish cells that express the protein from cells that do not. Proteins whose expression can be readily detected such as a fluorescent or luminescent protein or an enzyme that acts on a substrate to produce a colored, fluorescent, or luminescent substance (“detectable markers”) constitute a subset of selectable markers. The presence of a selectable marker linked to expression control elements native to a gene that is normally expressed selectively or exclusively in pluripotent cells makes it possible to identify and select somatic cells that have been reprogrammed to a pluripotent state. A variety of selectable marker genes can be used, such as neomycin resistance gene (neo), puromycin resistance gene (puro), guanine phosphoribosyl transferase (gpt), dihydrofolate reductase (DHFR), adenosine deaminase (ada), puromycin-N-acetyltransferase (PAC), hygromycin resistance gene (hyg), multidrug resistance gene (mdr), thymidine kinase (TK), hypoxanthine-guanine phosphoribosyltransferase (HPRT), and hisD gene. Detectable markers include green fluorescent protein (GFP) blue, sapphire, yellow, red, orange, and cyan fluorescent proteins and variants of any of these. Luminescent proteins such as luciferase (e.g., firefly or Renilla luciferase) are also of use. As will be evident to one of skill in the art, the term “selectable marker” as used herein can refer to a gene or to an expression product of the gene, e.g., an encoded protein.
In some embodiments the selectable marker confers a proliferation and/or survival advantage on cells that express it relative to cells that do not express it or that express it at significantly lower levels. Such proliferation and/or survival advantage typically occurs when the cells are maintained under certain conditions, i.e., “selective conditions.” To ensure an effective selection, a population of cells can be maintained under conditions and for a sufficient period of time such that cells that do not express the marker do not proliferate and/or do not survive and are eliminated from the population or their number is reduced to only a very small fraction of the population. The process of selecting cells that express a marker that confers a proliferation and/or survival advantage by maintaining a population of cells under selective conditions so as to largely or completely eliminate cells that do not express the marker is referred to herein as “positive selection”, and the marker is said to be “useful for positive selection”. Negative selection and markers useful for negative selection are also of interest in certain of the methods described herein. Expression of such markers confers a proliferation and/or survival disadvantage on cells that express the marker relative to cells that do not express the marker or express it at significantly lower levels (or, considered another way, cells that do not express the marker have a proliferation and/or survival advantage relative to cells that express the marker). Cells that express the marker can therefore be largely or completely eliminated from a population of cells when maintained in selective conditions for a sufficient period of time.
A “reporter gene” as used herein encompasses any gene that is genetically introduced into a cell that adds to the phenotype of the stem cell. Reporter genes as disclosed in this invention are intended to encompass fluorescent, luminescent, enzymatic and resistance genes, but also other genes which can easily be detected by persons of ordinary skill in the art. In some embodiments of the invention, reporter genes are used as markers for the identification of particular stem cells, cardiovascular stem cells and their differentiated progeny. A reporter gene is generally operatively linked to sequences that regulate its expression in a manner dependent upon one or more conditions which are monitored by measuring expression of the reporter gene. In some cases, expression of the reporter gene may be determined in live cells. Where live cell reporter gene assays are used, reporter gene expression may be monitored at multiple time points, e.g., 2, 3, 4, 5, 6, 8, or 10 or more time points. In some cases, where a live cell reporter assay is used, reporter gene expression is monitored with a frequency of at least about 10 minutes to about 24 hours, e.g., 20 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 18 hours, or another frequency from any integer between about 10 minutes to about 24 hours.
The terms “subject” and “individual” are used interchangeably herein, and refer to an animal, for example, a human from whom cells can be obtained and/or to whom treatment, including prophylactic treatment, with the cells as described herein, is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human subject, the term subject refers to that specific animal. The “non-human animals” and “non-human mammals” as used interchangeably herein, includes mammals such as rats, mice, rabbits, sheep, cats, dogs, cows, pigs, and non-human primates. The term “subject” also encompasses any vertebrate including but not limited to mammals, reptiles, amphibians and fish. However, advantageously, the subject is a mammal such as a human, or other mammals such as a domesticated mammal, e.g. dog, cat, horse, and the like, or production mammal, e.g. cow, sheep, pig, and the like.
The terms “treat”, “treating”, “treatment”, etc., as applied to an isolated cell, include subjecting the cell to any kind of process or condition or performing any kind of manipulation or procedure on the cell. As applied to a subject, the terms refer to providing medical or surgical attention, care, or management to an individual. The individual is usually ill or injured, or at increased risk of becoming ill relative to an average member of the population and in need of such attention, care, or management.
As used herein, the term “treating” and “treatment” refers to administering to a subject an effective amount of a composition so that the subject as a reduction in at least one symptom of the disease or an improvement in the disease, for example, beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. Treating can refer to prolonging survival as compared to expected survival if not receiving treatment. Thus, one of skill in the art realizes that a treatment may improve the disease condition, but may not be a complete cure for the disease. As used herein, the term “treatment” includes prophylaxis. Alternatively, treatment is “effective” if the progression of a disease is reduced or halted. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
As used herein, the terms “administering,” “introducing” and “transplanting” are used interchangeably in the context of the placement of cells of the invention into a subject, by a method or route which results in at least partial localization of the introduced cells at a desired site. The cells can be implanted directly to the pancreas or gastrointestinal tract, or alternatively be administered by any appropriate route which results in delivery to a desired location in the subject where at least a portion of the implanted cells or components of the cells remain viable. The period of viability of the cells after administration to a subject can be as short as a few hours, e.g. twenty-four hours, to a few days, to as long as several years. In some instances, the cells can also be administered subcutaneously, for example, in a capsule (e.g., microcapsule) to maintain the implanted cells at the implant location and avoid migration of the implanted cells.
The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. The phrases “systemic administration,” “administered systemically”, “peripheral administration” and “administered peripherally” as used herein mean the administration of stem cell-derived cells and/or their progeny and/or compound and/or other material other than directly into the central nervous system, such that it enters the animal's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
The term “tissue” refers to a group or layer of specialized cells which together perform certain special functions. The term “tissue-specific” refers to a source of cells from a specific tissue.
The terms “decrease,” “reduced,” “reduction,” “decrease,” or “inhibit” are all used herein generally to mean a decrease by a statistically significant amount. However, for avoidance of doubt, “reduced”, “reduction” or “decrease” or “inhibit” means a decrease by at least 10% as compared to a reference level, for example a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (i.e. absent level as compared to a reference sample), or any decrease between 10-100% as compared to a reference level.
The terms “increased,” “increase,” “enhance,” or “activate” are all used herein to generally mean an increase by a statically significant amount; for the avoidance of any doubt, the terms “increased,” “increase,” “enhance,” or “activate” means an increase of at least 10% as compared to a reference level, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level. The term “statistically significant” or “significantly” refers to statistical significance and generally means a two standard deviation (2SD) below normal, or lower, concentration of the marker. The term refers to statistical evidence that there is a difference. It is defined as the probability of making a decision to reject the null hypothesis when the null hypothesis is actually true. The decision is often made using the p-value.
As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are essential to the invention, yet open to the inclusion of unspecified elements, whether essential or not.
As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus for example, references to “the method” includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
Stem Cells Stem cells are cells that retain the ability to renew themselves through mitotic cell division and can differentiate into a diverse range of specialized cell types. The two broad types of mammalian stem cells are: embryonic stem (ES) cells that are found in blastocysts, and adult stem cells that are found in adult tissues. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells, but also maintain the normal turnover of regenerative organs, such as blood, skin or intestinal tissues. Pluripotent stem cells can differentiate into cells derived from any of the three germ layers.
While certain embodiments are described below in reference to the use of stem cells, germ cells may be used in place of, or with, the stem cells to provide at least one differentiated cell, using similar protocols as the illustrative protocols described herein. Suitable germ cells can be prepared, for example, from primordial germ cells present in human fetal material taken about 8-11 weeks after the last menstrual period. Illustrative germ cell preparation methods are described, for example, in Shamblott et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998 and U.S. Pat. No. 6,090,622.
ES cells, e.g., human embryonic stem cells (hESCs) or mouse embryonic stem cells (mESCs), with a virtually endless replication capacity and the potential to differentiate into most cell types, present, in principle, an unlimited starting material to generate the differentiated cells for clinical therapy (stemcells.nih.gov/info/scireport/2006report.htm, 2006).
hESC cells, are described, for example, by Cowan et al. (N Engl. J. Med. 350:1353, 2004) and Thomson et al. (Science 282:1145, 1998); embryonic stem cells from other primates, Rhesus stem cells (Thomson et al., Proc. Natl. Acad. Sci. USA 92:7844, 1995), marmoset stem cells (Thomson et al., Biol. Reprod. 55:254, 1996) and human embryonic germ (hEG) cells (Shamblott et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998) may also be used in the methods disclosed herein. mESCs, are described, for example, by Tremml et al. (Curr Protoc Stem Cell Biol. Chapter 1:Unit 1C.4, 2008). The stem cells may be, for example, unipotent, totipotent, multipotent, or pluripotent. In some examples, any cells of primate origin that are capable of producing progeny that are derivatives of at least one germinal layer, or all three germinal layers, may be used in the methods disclosed herein.
In certain examples, ES cells may be isolated, for example, as described in Cowan et al. (N Engl. J. Med. 350:1353, 2004) and U.S. Pat. No. 5,843,780 and Thomson et al., Proc. Natl. Acad. Sci. USA 92:7844, 1995. For example, hESCs cells can be prepared from human blastocyst cells using the techniques described by Thomson et al. (U.S. Pat. No. 6,200,806; Science 282:1145, 1998; Curr. Top. Dev. Biol. 38:133 ff., 1998) and Reubinoff et al, Nature Biotech. 18:399, 2000. Equivalent cell types to hESCs include their pluripotent derivatives, such as primitive ectoderm-like (EPL) cells, as outlined, for example, in WO 01/51610 (Bresagen). hESCs can also be obtained from human pre-implantation embryos. Alternatively, in vitro fertilized (IVF) embryos can be used, or one-cell human embryos can be expanded to the blastocyst stage (Bongso et al., Hum Reprod 4: 706, 1989). Embryos are cultured to the blastocyst stage in G1.2 and G2.2 medium (Gardner et al., Fertil. Steril. 69:84, 1998). The zona pellucida is removed from developed blastocysts by brief exposure to pronase (Sigma). The inner cell masses can be isolated by immunosurgery, in which blastocysts are exposed to a 1:50 dilution of rabbit anti-human spleen cell antiserum for 30 min, then washed for 5 min three times in DMEM, and exposed to a 1:5 dilution of Guinea pig complement (Gibco) for 3 min (Solter et al., Proc. Natl. Acad. Sci. USA 72:5099, 1975). After two further washes in DMEM, lysed trophectoderm cells are removed from the intact inner cell mass (ICM) by gentle pipetting, and the ICM plated on mEF feeder layers. After 9 to 15 days, inner cell mass-derived outgrowths can be dissociated into clumps, either by exposure to calcium and magnesium-free phosphate-buffered saline (PBS) with 1 mM EDTA, by exposure to dispase or trypsin, or by mechanical dissociation with a micropipette; and then replated on mEF in fresh medium. Growing colonies having undifferentiated morphology can be individually selected by micropipette, mechanically dissociated into clumps, and replated. ES-like morphology is characterized as compact colonies with apparently high nucleus to cytoplasm ratio and prominent nucleoli. Resulting hESCs can then be routinely split every 1-2 weeks, for example, by brief trypsinization, exposure to Dulbecco's PBS (containing 2 mM EDTA), exposure to type IV collagenase (about 200 U/mL; Gibco) or by selection of individual colonies by micropipette. In some examples, clump sizes of about 50 to 100 cells are optimal. mESCs cells can be prepared from using the techniques described by e.g., Conner et al. (Curr. Prot. in Mol. Biol. Unit 23.4, 2003).
Embryonic stem cells can be isolated from blastocysts of members of the primate species (U.S. Pat. No. 5,843,780; Thomson et al., Proc. Natl. Acad. Sci. USA 92:7844, 1995). Human embryonic stem (hES) cells can be prepared from human blastocyst cells using the techniques described by Thomson et al. (U.S. Pat. No. 6,200,806; Science 282:1145, 1998; Curr. Top. Dev. Biol. 38:133 ff., 1998) and Reubinoff et al, Nature Biotech. 18:399, 2000. Equivalent cell types to hES cells include their pluripotent derivatives, such as primitive ectoderm-like (EPL) cells, as outlined in WO 01/51610 (Bresagen).
Alternatively, in some embodiments, hES cells can be obtained from human preimplantation embryos. Alternatively, in vitro fertilized (IVF) embryos can be used, or one-cell human embryos can be expanded to the blastocyst stage (Bongso et al., Hum Reprod 4: 706, 1989). Embryos are cultured to the blastocyst stage in G1.2 and G2.2 medium (Gardner et al., Fertil. Steril. 69:84, 1998). The zona pellucida is removed from developed blastocysts by brief exposure to pronase (Sigma). The inner cell masses are isolated by immunosurgery, in which blastocysts are exposed to a 1:50 dilution of rabbit anti-human spleen cell antiserum for 30 min, then washed for 5 min three times in DMEM, and exposed to a 1:5 dilution of Guinea pig complement (Gibco) for 3 min (Solter et al., Proc. Natl. Acad. Sci. USA 72:5099, 1975). After two further washes in DMEM, lysed trophectoderm cells are removed from the intact inner cell mass (ICM) by gentle pipetting, and the ICM plated on mEF feeder layers.
After 9 to 15 days, inner cell mass-derived outgrowths are dissociated into clumps, either by exposure to calcium and magnesium-free phosphate-buffered saline (PBS) with 1 mM EDTA, by exposure to dispase or trypsin, or by mechanical dissociation with a micropipette; and then replated on mEF in fresh medium. Growing colonies having undifferentiated morphology are individually selected by micropipette, mechanically dissociated into clumps, and replated. ES-like morphology is characterized as compact colonies with apparently high nucleus to cytoplasm ratio and prominent nucleoli. Resulting ES cells are then routinely split every 1-2 weeks by brief trypsinization, exposure to Dulbecco's PBS (containing 2 mM EDTA), exposure to type IV collagenase 0200 U/mL; Gibco) or by selection of individual colonies by micropipette. Clump sizes of about 50 to 100 cells are optimal.
In some embodiments, human Embryonic Germ (hEG) cells are pluripotent stem cells which can be used in the methods as disclosed herein to differentiate into primitive endoderm cells. hEG cells can be prepared from primordial germ cells present in human fetal material taken about 8-11 weeks after the last menstrual period. Suitable preparation methods are described in Shamblott et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998 and U.S. Pat. No. 6,090,622, which is incorporated herein in its entirety by reference.
Briefly, genital ridges are processed to form disaggregated cells. EG growth medium is DMEM, 4500 mg/L D-glucose, 2200 mg/L mM NaHCO3; 15% ES qualified fetal calf serum (BRL); 2 mM glutamine (BRL); 1 mM sodium pyruvate (BRL); 1000-2000 U/mL human recombinant leukemia inhibitory factor (LIF, Genzyme); 1-2 ng/mL human recombinant bFGF (Genzyme); and 10 μM forskolin (in 10% DMSO). Ninety-six well tissue culture plates are prepared with a sub-confluent layer of feeder cells (e.g., STO cells, ATCC No. CRL 1503) cultured for 3 days in modified EG growth medium free of LIF, bFGF or forskolin, inactivated with 5000 rad γ-irradiation ˜0.2 mL of primary germ cell (PGC) suspension is added to each of the wells. The first passage is done after 7-10 days in EG growth medium, transferring each well to one well of a 24-well culture dish previously prepared with irradiated STO mouse fibroblasts. The cells are cultured with daily replacement of medium until cell morphology consistent with EG cells is observed, typically after 7-30 days or 1-4 passages.
In certain examples, the stem cells can be undifferentiated (e.g. a cell not committed to a specific lineage) prior to exposure to at least one maturation factor according to the methods as disclosed herein, whereas in other examples it may be desirable to differentiate the stem cells to one or more intermediate cell types prior to exposure of the at least one maturation factor (s) described herein. For example, the stem cells may display morphological, biological or physical characteristics of undifferentiated cells that can be used to distinguish them from differentiated cells of embryo or adult origin. In some examples, undifferentiated cells may appear in the two dimensions of a microscopic view in colonies of cells with high nuclear/cytoplasmic ratios and prominent nucleoli. The stem cells may be themselves (for example, without substantially any undifferentiated cells being present) or may be used in the presence of differentiated cells. In certain examples, the stem cells may be cultured in the presence of suitable nutrients and optionally other cells such that the stem cells can grow and optionally differentiate. For example, embryonic fibroblasts or fibroblast-like cells may be present in the culture to assist in the growth of the stem cells. The fibroblast may be present during one stage of stem cell growth but not necessarily at all stages. For example, the fibroblast may be added to stem cell cultures in a first culturing stage and not added to the stem cell cultures in one or more subsequent culturing stages.
Stem cells used in all aspects of the present invention can be any cells derived from any kind of tissue (for example embryonic tissue such as fetal or pre-fetal tissue, or adult tissue), which stem cells have the characteristic of being capable under appropriate conditions of producing progeny of different cell types, e.g. derivatives of all of at least one of the 3 germinal layers (endoderm, mesoderm, and ectoderm). These cell types may be provided in the form of an established cell line, or they may be obtained directly from primary embryonic tissue and used immediately for differentiation. Included are cells listed in the NIH Human Embryonic Stem Cell Registry, e.g. hESBGN-01, hESBGN-02, hESBGN-03, hESBGN-04 (BresaGen, Inc.); HES-1, HES-2, HES-3, HES-4, HES-5, HES-6 (ES Cell International); Miz-hES1 (MizMedi Hospital-Seoul National University); HSF-1, HSF-6 (University of California at San Francisco); and H1, H7, H9, H13, H14 (Wisconsin Alumni Research Foundation (WiCell Research Institute)). In some embodiments, the source of human stem cells or pluripotent stem cells used for chemically-induced differentiation into stem cell-derived cells did not involve destroying a human embryo.
In another embodiment, the stem cells can be isolated from tissue including solid tissue. In some embodiments, the tissue is skin, fat tissue (e.g. adipose tissue), muscle tissue, heart or cardiac tissue. In other embodiments, the tissue is for example but not limited to, umbilical cord blood, placenta, bone marrow, or chondral.
Stem cells of interest also include embryonic cells of various types, exemplified by human embryonic stem (hES) cells, described by Thomson et al. (1998) Science 282:1145; embryonic stem cells from other primates, such as Rhesus stem cells (Thomson et al. (1995) Proc. Natl. Acad. Sci. USA 92:7844); marmoset stem cells (Thomson et al. (1996) Biol. Reprod. 55:254); and human embryonic germ (hEG) cells (Shambloft et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998). Also of interest are lineage committed stem cells, such as mesodermal stem cells and other early cardiogenic cells (see Reyes et al. (2001) Blood 98:2615-2625; Eisenberg & Bader (1996) Circ Res. 78(2):205-16; etc.) The stem cells may be obtained from any mammalian species, e.g. human, equine, bovine, porcine, canine, feline, rodent, e.g. mice, rats, hamster, primate, etc. In some embodiments, a human embryo was not destroyed for the source of pluripotent cell used on the methods and compositions as disclosed herein.
ES cells are considered to be undifferentiated when they have not committed to a specific differentiation lineage. Such cells display morphological characteristics that distinguish them from differentiated cells of embryo or adult origin. Undifferentiated ES cells are easily recognized by those skilled in the art, and typically appear in the two dimensions of a microscopic view in colonies of cells with high nuclear/cytoplasmic ratios and prominent nucleoli. Undifferentiated ES cells express genes that may be used as markers to detect the presence of undifferentiated cells, and whose polypeptide products may be used as markers for negative selection. For example, see U.S. application Ser. No. 2003/0224411 A1; Bhattacharya (2004) Blood 103(8):2956-64; and Thomson (1998), supra., each herein incorporated by reference. Human ES cell lines express cell surface markers that characterize undifferentiated nonhuman primate ES and human EC cells, including stage-specific embryonic antigen (SSEA)-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase. The globo-series glycolipid GL7, which carries the SSEA-4 epitope, is formed by the addition of sialic acid to the globo-series glycolipid GbS, which carries the SSEA-3 epitope. Thus, GL7 reacts with antibodies to both SSEA-3 and SSEA-4. The undifferentiated human ES cell lines did not stain for SSEA-1, but differentiated cells stained strongly for SSEA-I. Methods for proliferating hES cells in the undifferentiated form are described in WO 99/20741, WO 01/51616, and WO 03/020920.
A mixture of cells from a suitable source of endothelial, muscle, and/or neural stem cells can be harvested from a mammalian donor by methods known in the art. A suitable source is the hematopoietic microenvironment. For example, circulating peripheral blood, preferably mobilized (i.e., recruited), may be removed from a subject. Alternatively, bone marrow may be obtained from a mammal, such as a human patient, undergoing an autologous transplant. In some embodiments, stem cells can be obtained from the subjects adipose tissue, for example using the CELUTION™ SYSTEM from Cytori, as disclosed in U.S. Pat. Nos. 7,390,484 and 7,429,488 which is incorporated herein in its entirety by reference.
In some embodiments, human umbilical cord blood cells (HUCBC) are useful in the methods as disclosed herein. Human UBC cells are recognized as a rich source of hematopoietic and mesenchymal progenitor cells (Broxmeyer et al., 1992 Proc. Natl. Acad. Sci. USA 89:4109-4113). Previously, umbilical cord and placental blood were considered a waste product normally discarded at the birth of an infant. Cord blood cells are used as a source of transplantable stem and progenitor cells and as a source of marrow repopulating cells for the treatment of malignant diseases (i.e. acute lymphoid leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, and nueroblastoma) and non-malignant diseases such as Fanconi's anemia and aplastic anemia (Kohli-Kumar et al., 1993 Br. J. Haematol. 85:419-422; Wagner et al., 1992 Blood 79; 1874-1881; Lu et al., 1996 Crit. Rev. Oncol. Hematol 22:61-78; Lu et al., 1995 Cell Transplantation 4:493-503). A distinct advantage of HUCBC is the immature immunity of these cells that is very similar to fetal cells, which significantly reduces the risk for rejection by the host (Taylor & Bryson, 1985J. Immunol. 134:1493-1497). Human umbilical cord blood contains mesenchymal and hematopoietic progenitor cells, and endothelial cell precursors that can be expanded in tissue culture (Broxmeyer et al., 1992 Proc. Natl. Acad. Sci. USA 89:4109-4113; Kohli-Kumar et al., 1993 Br. J. Haematol. 85:419-422; Wagner et al., 1992 Blood 79; 1874-1881; Lu et al., 1996 Crit. Rev. Oncol. Hematol 22:61-78; Lu et al., 1995 Cell Transplantation 4:493-503; Taylor & Bryson, 1985J. Immunol. 134:1493-1497 Broxmeyer, 1995 Transfusion 35:694-702; Chen et al., 2001 Stroke 32:2682-2688; Nieda et al., 1997 Br. J. Haematology 98:775-777; Erices et al., 2000 Br. J. Haematology 109:235-242). The total content of hematopoietic progenitor cells in umbilical cord blood equals or exceeds bone marrow, and in addition, the highly proliferative hematopoietic cells are eightfold higher in HUCBC than in bone marrow and express hematopoietic markers such as CD14, CD34, and CD45 (Sanchez-Ramos et al., 2001 Exp. Neur. 171:109-115; Bicknese et al., 2002 Cell Transplantation 11:261-264; Lu et al., 1993 J. Exp Med. 178:2089-2096).
In another embodiment, pluripotent cells are cells in the hematopoietic microenvironment, such as the circulating peripheral blood, preferably from the mononuclear fraction of peripheral blood, umbilical cord blood, bone marrow, fetal liver, or yolk sac of a mammal. The stem cells, especially neural stem cells, may also be derived from the central nervous system, including the meninges.
In another embodiment, pluripotent cells are present in embryoid bodies are formed by harvesting ES cells with brief protease digestion, and allowing small clumps of undifferentiated human ESCs to grow in suspension culture. Differentiation is induced by withdrawal of conditioned medium. The resulting embryoid bodies are plated onto semi-solid substrates. Formation of differentiated cells may be observed after around about 7 days to around about 4 weeks. Viable differentiating cells from in vitro cultures of stem cells are selected for by partially dissociating embryoid bodies or similar structures to provide cell aggregates. Aggregates comprising cells of interest are selected for phenotypic features using methods that substantially maintain the cell to cell contacts in the aggregate.
In an alternative embodiment, the stem cells can be reprogrammed stem cells, such as stem cells derived from somatic or differentiated cells. In such an embodiment, the de-differentiated stem cells can be for example, but not limited to, neoplastic cells, tumor cells and cancer cells or alternatively induced reprogrammed cells such as induced pluripotent stem cells or iPS cells.
Cloning and Cell Culture
Illustrative methods for molecular genetics and genetic engineering that may be used in the technology described herein may be found, for example, in current editions of Molecular Cloning: A Laboratory Manual, (Sambrook et al., Cold Spring Harbor); Gene Transfer Vectors for Mammalian Cells (Miller & Calos eds.); and Current Protocols in Molecular Biology (F. M. Ausubel et al. eds., Wiley & Sons). Cell biology, protein chemistry, and antibody techniques can be found, for example, in Current Protocols in Protein Science (J. E. Colligan et al. eds., Wiley & Sons); Current Protocols in Cell Biology (J. S. Bonifacino et al., Wiley & Sons) and Current protocols in Immunology (J. E. Colligan et al. eds., Wiley & Sons.). Illustrative reagents, cloning vectors, and kits for genetic manipulation may be commercially obtained, for example, from BioRad, Stratagene, Invitrogen, ClonTech, and Sigma-Aldrich Co.
Suitable cell culture methods may be found, for example, in Cell culture methods are described generally in the current edition of Culture of Animal Cells: A Manual of Basic Technique (R. I. Freshney ed., Wiley & Sons); General Techniques of Cell Culture (M. A. Harrison & I. F. Rae, Cambridge Univ. Press), and Embryonic Stem Cells: Methods and Protocols (K. Turksen ed., Humana Press). Suitable tissue culture supplies and reagents are commercially available, for example, from Gibco/BRL, Nalgene-Nunc International, Sigma Chemical Co., and ICN Biomedicals.
Pluripotent stem cells can be propagated by one of ordinary skill in the art and continuously in culture, using culture conditions that promote proliferation without promoting differentiation. Exemplary serum-containing ES medium is made with 80% DMEM (such as Knock-Out DMEM, Gibco), 20% of either defined fetal bovine serum (FBS, Hyclone) or serum replacement (WO 98/30679), 1% non-essential amino acids, 1 mM L-glutamine, and 0.1 mM β-mercaptoethanol. Just before use, human bFGF is added to 4 ng/mL (WO 99/20741, Geron Corp.). Traditionally, ES cells are cultured on a layer of feeder cells, typically fibroblasts derived from embryonic or fetal tissue.
Scientists at Geron have discovered that pluripotent SCs can be maintained in an undifferentiated state even without feeder cells. The environment for feeder-free cultures includes a suitable culture substrate, particularly an extracellular matrix such as Matrigel® or laminin. Typically, enzymatic digestion is halted before cells become completely dispersed (say, ˜5 min with collagenase IV). Clumps of ˜10 to 2,000 cells are then plated directly onto the substrate without further dispersal.
Feeder-free cultures are supported by a nutrient medium containing factors that support proliferation of the cells without differentiation. Such factors may be introduced into the medium by culturing the medium with cells secreting such factors, such as irradiated (4,000 rad) primary mouse embryonic fibroblasts, telomerized mouse fibroblasts, or fibroblast-like cells derived from pPS cells. Medium can be conditioned by plating the feeders at a density of ˜5-6×104 cm−2 in a serum free medium such as KO DMEM supplemented with 20% serum replacement and 4 ng/mL bFGF. Medium that has been conditioned for 1-2 days is supplemented with further bFGF, and used to support pluripotent SC culture for 1-2 days. Features of the feeder-free culture method are further discussed in International Patent Publication WO 01/51616; and Xu et al., Nat. Biotechnol. 19:971, 2001.
Under the microscope, ES cells appear with high nuclear/cytoplasmic ratios, prominent nucleoli, and compact colony formation with poorly discernable cell junctions. Primate ES cells express stage-specific embryonic antigens (SSEA) 3 and 4, and markers detectable using antibodies designated Tra-1-60 and Tra-1-81 (Thomson et al., Science 282:1145, 1998). Mouse ES cells can be used as a positive control for SSEA-1, and as a negative control for SSEA-4, Tra-1-60, and Tra-1-81. SSEA-4 is consistently present human embryonal carcinoma (hEC) cells. Differentiation of pluripotent SCs in vitro results in the loss of SSEA-4, Tra-1-60, and Tra-1-81 expression, and increased expression of SSEA-1, which is also found on undifferentiated hEG cells.
Methods of Generating Stem Cell-Derived Cells
Aspects of the disclosure relate to generating stem cell-derived cells (e.g., SC-β cells, SC-EC cells, SC-α cells, etc.). Generally, the at least one stem cell-derived cell or precursor thereof, e.g., pancreatic progenitors produced according to the methods disclosed herein can comprise a mixture or combination of different cells, e.g., for example a mixture of cells such as a Pdx1+ pancreatic progenitors, pancreatic progenitors co-expressing Pdx1 and NKX6-1, Ngn3-positive endocrine progenitors, endocrine cells (e.g., β-like cells, a-like cells, EC-like cells), non-endocrine cells, and/or other pluripotent or stem cells.
The at least one stem cell-derived cell or precursor thereof can be produced according to any suitable culturing protocol to differentiate a stem cell or pluripotent cell to a desired stage of differentiation. In some embodiments, the at least one stem cell-derived cell or the precursor thereof are produced by culturing at least one pluripotent cell for a period of time and under conditions suitable for the at least one pluripotent cell to differentiate into the at least one stem cell-derived cell or the precursor thereof.
In some embodiments, the at least one stem cell-derived cell or precursor thereof is a substantially pure population of stem cell-derived cells or precursors thereof. In some embodiments, a population of stem cell-derived cells or precursors thereof comprises a mixture of pluripotent cells or differentiated cells (e.g., a mixture of SC-β cells and SC-EC cells). In some embodiments, a population SC-β cells or precursors thereof are substantially free or devoid of embryonic stem cells or pluripotent cells or iPS cells.
In some embodiments, a somatic cell, e.g., fibroblast can be isolated from a subject, for example as a tissue biopsy, such as, for example, a skin biopsy, and reprogrammed into an induced pluripotent stem cell for further differentiation to produce the at least one stem cell-derived cell or precursor thereof for use in the compositions and methods described herein. In some embodiments, a somatic cell, e.g., fibroblast is maintained in culture by methods known by one of ordinary skill in the art, and in some embodiments, propagated prior to being converted into stem cell-derived cells by the methods as disclosed herein.
In some embodiments, the at least one stem cell-derived cell or precursor thereof is maintained in culture by methods known by one of ordinary skill in the art, and in some embodiments, propagated prior to being converted into stem cell-derived cells by the methods as disclosed herein.
Further, at least one stem cell-derived cell or precursor thereof, e.g., pancreatic progenitor can be from any mammalian species, with non-limiting examples including a murine, bovine, simian, porcine, equine, ovine, or human cell. For clarity and simplicity, the description of the methods herein refers to a mammalian at least one stem cell-derived cell or precursor thereof but it should be understood that all of the methods described herein can be readily applied to other cell types of at least one stem cell-derived cell or precursor thereof. In some embodiments, the at least one stem cell-derived cell or precursor thereof is derived from a human individual.
In some embodiments stem cell-derived cells may be produced using the methods disclosed in WO 2015/002724 and WO 2014/201167, both of which are incorporated herein by reference.
In some embodiments the methods disclosed in WO 2015/002724 and WO 2014/201167 are altered or modified (e.g., at Stages 3 and 4). In some embodiments, Pdx1+ pancreatic progenitor cells are obtained at Stage 3 of a differentiation protocol by differentiating at least some primitive gut tube cells in a population into Pdx1+ pancreatic progenitor cells, e.g., by contacting the primitive gut tube cells with i) at least one bone morphogenic protein (BMP) signaling pathway inhibitor and ii) at least one retinoic acid (RA) signaling pathway activator, to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells, wherein the Pdx1+ pancreatic progenitor cells express Pdx1. In other embodiments, Pdx1+ pancreatic progenitor cells can be obtained by differentiating at least some primitive gut tube cells in a population into Pdx1+ pancreatic progenitor cells, e.g., by contacting the primitive gut tube cells with i) at least one growth factor from the FGF family and ii) at least one retinoic acid (RA) signaling pathway activator, to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells, wherein the Pdx1+ pancreatic progenitor cells express
Pdx1.
The disclosure contemplates the use of any BMP signaling pathway inhibitor that induces primitive gut tube cells to differentiate into Pdx1+ pancreatic progenitor cells. In some embodiments, the BMP signaling pathway inhibitor comprises LDN193189.
The disclosure contemplates the use of any growth factor from the FGF family that induces primitive gut tube cells to differentiate into Pdx1+ pancreatic progenitor cells. In some embodiments, the at least one growth factor from the FGF family comprises keratinocyte growth factor (KGF).
The disclosure contemplates the use of any RA signaling pathway activator that induces primitive gut tube cells to differentiate into Pdx1+ pancreatic progenitor cells. In some embodiments, the RA signaling pathway activator comprises retinoic acid.
The skilled artisan will appreciate that the concentrations of agents employed may vary. In some embodiments, the primitive gut tube cells are contacted with the BMP signaling pathway inhibitor at a concentration of between 20 nM-2000 nM. In some embodiments, the primitive gut tube cells are contacted with the BMP signaling pathway inhibitor at a concentration of 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, or 190 nM. In some embodiments, the primitive gut tube cells are contacted with the BMP signaling pathway inhibitor at a concentration of 191 nM, 192 nM, 193 nM, 194 nM, 195 nM, 196 nM, 197 nM, 198 nM, or 199 nM. In some embodiments, the primitive gut tube cells are contacted with the BMP signaling pathway inhibitor at a concentration of 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1000 nM, 1100 nM, 1200 nM, 1300 nM, 1400 nM, 1500 nM, 1600 nM, 1700 nM, 1800 nM, or 1900 nM. In some embodiments, the primitive gut tube cells are contacted with the BMP signaling pathway inhibitor at a concentration of 210 nM, 220 nM, 230 nM, 240 nM, 250 nM, 260 nM, 270 nM, 280 nM, or 290 nM. In some embodiments, the primitive gut tube cells are contacted with the BMP signaling pathway inhibitor at a concentration of 200 nM.
In some embodiments, the primitive gut tube cells are contacted with the at least one growth factor from the FGF family at a concentration of between 5 ng/mL-500 ng/mL. In some embodiments, the primitive gut tube cells are contacted with the at least one growth factor from the FGF family at a concentration of 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 35 ng/mL, or 40 ng/mL. In some embodiments, the primitive gut tube cells are contacted with the at least one growth factor from the FGF family at a concentration of 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, 80 ng/mL, 85 ng/mL, 90 ng/mL, 95 ng/mL or 100 ng/mL. In some embodiments, the primitive gut tube cells are contacted with the at least one growth factor from the FGF family at a concentration of 41 ng/mL, 42 ng/mL, 43 ng/mL, 44 ng/mL, 45 ng/mL, 46 ng/mL, 47 ng/mL, 48 ng/mL or 49 ng/mL. In some embodiments, the primitive gut tube cells are contacted with the at least one growth factor from the FGF family at a concentration of 51 ng/mL, 52 ng/mL, 53 ng/mL, 54 ng/mL, 55 ng/mL, 56 ng/mL, 57 ng/mL, 58 ng/mL or 59 ng/mL. In some embodiments, the primitive gut tube cells are contacted with the at least one growth factor from the FGF family at a concentration of 50 ng/mL.
In some embodiments, the primitive gut tube cells are contacted with the RA signaling pathway activator at a concentration of between 0.01 μM-1.0 μM. In some embodiments, the primitive gut tube cells are contacted with the RA signaling pathway activator at a concentration of 0.02 μM, 0.03 μM, 0.04 μM, 0.05 μM, 0.06 μM, 0.07 μM, 0.08 μM, or 0.09 μM. In some embodiments, the primitive gut tube cells are contacted with the RA signaling pathway activator at a concentration of 0.20 μM, 0.30 μM, 0.40 μM, 0.50 μM, 0.60 μM, 0.70 μM, 0.80 μM, or 0.90 μM. In some embodiments, the primitive gut tube cells are contacted with the RA signaling pathway activator at a concentration of 0.1 μM.
Generally, the primitive gut tube cells are maintained in a suitable culture medium (e.g., suspension culture) for a period of time sufficient to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells. An exemplary suitable culture medium is shown in Table 1 below.
In some embodiments, S3 media can be used as a suitable culture medium for differentiating primitive gut tube cells into pancreatic progenitor cells.
In some embodiments, contacting the primitive gut tube cells is effected in suspension culture. In some embodiments, the suspension culture is maintained in a spinner flask. In some embodiments, the period of time is at least 2 days. In some embodiments, the suspension culture is replenished every day.
In some embodiments, Pdx1+ pancreatic progenitor cells can be obtained by differentiating at least some of the primitive gut tube cells in a population into Pdx1+ pancreatic progenitor cells, e.g., by contacting the primitive gut tube cells with i) LDN193189 and ii) RA, to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells, wherein the Pdx1+ pancreatic progenitor cells express Pdx1.
In some embodiments, Pdx1+ pancreatic progenitor cells can be obtained by differentiating at least some of the primitive gut tube cells in a population into Pdx1+ pancreatic progenitor cells, e.g., by contacting the primitive gut tube cells with i) KGF and ii) RA, to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells, wherein the Pdx1+ pancreatic progenitor cells express Pdx1. Pdx1+
In some embodiments, Pdx1+, NKX6-1+ pancreatic progenitor cell can be obtained at Stage 4 of a differentiation protocol by differentiating at least some Pdx1+ pancreatic progenitor cells in a population into Pdx1+, NKX6-1+ pancreatic progenitor cells, e.g., by contacting the Pdx1+ pancreatic progenitor cells with i) at least one growth factor from the fibroblast growth factor (FGF) family, to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells in the population into Pdx1+, NKX6-1+ pancreatic progenitor cells, wherein the Pdx1+, NKX6-1+ pancreatic progenitor cells express at least NKX6-1. In other embodiments, Pdx1+, NKX6-1+ pancreatic progenitor cell can be obtained by differentiating at least some Pdx1+ pancreatic progenitor cells in a population into NKX6-1 positive pancreatic progenitor cells, e.g., by contacting the Pdx1+ pancreatic progenitor cells with i) at least one retinoic acid (RA) signaling pathway activator and ii) at least one bone morphogenic protein (BMP) signaling pathway inhibitor, to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells in the population into Pdx1+, NKX6-1+ pancreatic progenitor cells, wherein the Pdx1+, NKX6-1+ pancreatic progenitor cells express at least NKX6-1.
The disclosure contemplates the use of any growth factor from the FGF family that induces Pdx1+ pancreatic progenitor cells to differentiate into Pdx1+, NKX6-1+ pancreatic progenitor cells. In some embodiments, the at least one growth factor from the FGF family comprises keratinocyte growth factor (KGF).
The disclosure contemplates the use of any RA signaling pathway activator that induces Pdx1+ pancreatic progenitor cells to differentiate into Pdx1+, NKX6-1+ pancreatic progenitor cells. In some embodiments, the RA signaling pathway activator comprises retinoic acid.
The disclosure contemplates the use of any BMP signaling pathway inhibitor that induces Pdx1+ pancreatic progenitor cells to differentiate into Pdx1+, NKX6-1+ pancreatic progenitor cells. In some embodiments, the BMP signaling pathway inhibitor comprises LDN193189.
The skilled artisan will appreciate that the concentrations of agents (e.g., growth factors) employed may vary. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the at least one growth factor from the FGF family at a concentration of between 1 ng/mL-100 ng/mL. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the at least one growth factor from the FGF family at a concentration of 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 35 ng/mL, or 40 ng/mL. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the at least one growth factor from the FGF family at a concentration of 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, 80 ng/mL, 85 ng/mL, 90 ng/mL, 95 ng/mL or 100 ng/mL. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the at least one growth factor from the FGF family at a concentration of 41 ng/mL, 42 ng/mL, 43 ng/mL, 44 ng/mL, 45 ng/mL, 46 ng/mL, 47 ng/mL, 48 ng/mL or 49 ng/mL. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the at least one growth factor from the FGF family at a concentration of 51 ng/mL, 52 ng/mL, 53 ng/mL, 54 ng/mL, 55 ng/mL, 56 ng/mL, 57 ng/mL, 58 ng/mL or 59 ng/mL. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the at least one growth factor from the FGF family at a concentration of 50 ng/mL.
In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of between 0.01 μM-1.0 μM. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of 0.02 μM, 0.03 μM, 0.04 μM, 0.05 μM, 0.06 μM, 0.07 μM, 0.08 μM, or 0.09 μM. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of 0.20 μM, 0.30 μM, 0.40 μM, 0.50 μM, 0.60 μM, 0.70 μM, 0.80 μM, or 0.90 μM. In some embodiments, the Pdx1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of 0.1 μM. Generally, the Pdx1+ pancreatic progenitor cells are maintained in a suitable culture medium for a period of time sufficient to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells in the population into Pdx1+, NKX6-1+ pancreatic progenitor cells. An exemplary suitable culture medium is shown in Table 1 above. In some embodiments, conditions that promote cell clustering comprise a suspension culture. In some embodiments, the suspension culture is maintained in a spinner flask. In some embodiments, the period of time is at least 5 days. In some embodiments, the suspension culture is replenished every other day.
In some embodiments, the maturation factors are replenished every other day.
In some embodiments, at least 10% of the Pdx1+ pancreatic progenitor cells in the population are induced to differentiate into Pdx1+, NKX6-1+ pancreatic progenitor cells. In some embodiments, at least 95% of the Pdx1+ pancreatic progenitor cells are induced to differentiate into Pdx1+, NKX6-1+ pancreatic progenitor cells.
Generally, any Pdx1+ pancreatic progenitor cell can be differentiated into a Pdx1+, NKX6-1+ pancreatic progenitor cell. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells express Pdx1, NKX6-1 and/or FoxA2.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are obtained by contacting Pdx1+ pancreatic progenitor cells under conditions that promote cell clustering with i) KGF to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells into Pdx1+, NKX6-1+ pancreatic progenitor cells, wherein the Pdx1+, NKX6-1+ pancreatic progenitor cells express at least Pdx1 and NKX6-1.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are obtained by contacting Pdx1+ pancreatic progenitor cells under conditions that promote cell clustering with i) RA and ii) LDN193189 to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells into Pdx1+, NKX6-1+ pancreatic progenitor cells, wherein the Pdx1+, NKX6-1+ pancreatic progenitor cells express at least Pdx1 and NKX6-1.
In some aspects, a method of producing an endocrine cell from a Pdx1+, NKX6-1+ pancreatic progenitor cell (e.g. during Stage 5 of a differentiation protocol) comprises contacting a population of cells (e.g., under conditions that promote cell clustering) comprising Pdx1+, NKX6-1+ pancreatic progenitor cells with at least two maturation factors comprising i) a TGF-β signaling pathway inhibitor and ii) a thyroid hormone signaling pathway activator, to induce the differentiation of at least one Pdx1+, NKX6-1+ pancreatic progenitor cell in the population into an endocrine cell.
The disclosure contemplates the use of any TGF-β signaling pathway inhibitor that induces the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells to differentiate into endocrine cells. In some embodiments, the TGF-β signaling pathway comprises TGF-β receptor type I kinase signaling. In some embodiments, the TGF-β signaling pathway inhibitor comprises Alk5 inhibitor II.
The disclosure contemplates the use of any thyroid hormone signaling pathway activator that induces the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells to differentiate into endocrine cells. In some embodiments, the thyroid hormone signaling pathway activator comprises triiodothyronine (T3).
In some embodiments, the method comprises contacting the population of cells (e.g., Pdx1+, NKX6-1+ pancreatic progenitor cells) with at least one additional maturation factor. In some embodiments, the method comprises contacting the Pdx1+ NKX6-1+ pancreatic progenitor cells with at least one of i) a SHH pathway inhibitor, ii) a RA signaling pathway activator, iii) a γ-secretase inhibitor, iv) at least one growth factor from the epidermal growth factor (EGF) family, or v) a BMP signaling pathway inhibitor.
In some embodiments, the at least one additional maturation factor comprises a γ-secretase inhibitor. The disclosure contemplates the use of any γ-secretase inhibitor that is capable of inducing the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells in a population into endocrine cells. In some embodiments, the γ-secretase inhibitor comprises XXI.
In some embodiments, the at least one additional maturation factor comprises a retinoic acid (RA) signaling pathway activator (e.g., a low concentration of an RA signaling pathway activator). The disclosure contemplates the use of any RA signaling pathway activator that induces the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells to differentiate into endocrine cells. In some embodiments, the RA signaling pathway activator comprises RA.
In some embodiments, the at least one additional maturation factor comprises a sonic hedgehog (SHH) pathway inhibitor. The disclosure contemplates the use of any SHH pathway inhibitor that induces the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells to differentiate into endocrine cells. In some embodiments, the SHH pathway inhibitor comprises Sant1.
In some embodiments, the at least one additional maturation factor comprises at least one growth factor from the EGF family. The disclosure contemplates the use of any growth factor from the EGF family that is capable of inducing the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells in a population into endocrine cells. In some embodiments, the at least one growth factor from the EGF family comprises betacellulin.
In some embodiments, the at least one additional maturation factor comprises a BMP signaling pathway inhibitor. The disclosure contemplates the use of BMP signaling pathway inhibitor that is capable of inducing the differentiation of Pdx1+, NKX6-1+ pancreatic progenitor cells in a population into endocrine cells. In some embodiments, the BMP signaling pathway inhibitor comprises LDN193189.
The skilled artisan will appreciate that the concentrations of agents employed may vary.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of between 100 nM-100 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of 10 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, or 900 nM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, or 9 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of 9.1 μM, 9.2 μM, 9.3 μM, 9.4 μM, 9.5 μM, 9.6 μM, 9.7 μM, 9.8 μM or 9.9 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of 11 μM, 12 μM, 13 μM, 14 μM, 15 μM, 16 μM, 17 μM, 18 μM, or 19 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one TGF-β signaling pathway inhibitor at a concentration of 10.1 μM, 10.2 μM, 10.3 μM, 10.4 μM, 10.5 μM, 10.6 μM, 10.7 μM, 10.8 μM or 10.9 μM.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the thyroid hormone signaling pathway activator at a concentration of between 0.1 μM-10 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the thyroid hormone signaling pathway activator at a concentration of 1 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the thyroid hormone signaling pathway activator at a concentration of 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, or 0.9 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the thyroid hormone signaling pathway activator at a concentration of 1.1 μM, 1.2 μM, 1.3 μM, 1.4 μM, 1.5 μM, 1.6 μM, 1.7 μM, 1.8 μM or 1.9 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the thyroid hormone signaling pathway activator at a concentration of 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, or 9 μM.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the γ-secretase inhibitor at a concentration of between 0.1 μM-10 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the γ-secretase inhibitor at a concentration of 1 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the γ-secretase inhibitor at a concentration of 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, or 0.9 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the γ-secretase inhibitor at a concentration of 1.1 μM, 1.2 μM, 1.3 μM, 1.4 μM, 1.5 μM, 1.6 μM, 1.7 μM, 1.8 μM or 1.9 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the γ-secretase inhibitor at a concentration of 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, or 9 μM.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one growth factor from the EGF family at a concentration of between 2 ng/mL-200 ng/mL. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one growth factor from the EGF family at a concentration of 3 ng/mL, 4 ng/mL, 5 ng/mL, 6 ng/mL, 7 ng/mL, 8 ng/mL, 9 ng/mL, 10 ng/mL, 11 ng/mL, 12 ng/mL, 13 ng/mL, 14 ng/mL, 15 ng/mL, 16 ng/mL, 17 ng/mL, 18 ng/mL, or 19 ng/mL. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one growth factor from the EGF family at a concentration of 30 ng/mL, 35 ng/mL, 40 ng/mL, 45 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, 80 ng/mL, 85 ng/mL, 90 ng/mL, 95 ng/mL, or 100 ng/mL. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one growth factor from the EGF family at a concentration of 21 ng/mL, 22 ng/mL, 23 ng/mL, 24 ng/mL, 25 ng/mL, 26 ng/mL, 27 ng/mL, 28 ng/mL or 29 ng/mL. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one growth factor from the EGF family at a concentration of 20 ng/mL.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of between 0.01 μM-1.0 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of 0.02 μM, 0.03 μM, 0.04 μM, 0.05 μM, 0.06 μM, 0.07 μM, 0.08 μM, or 0.09 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of 0.20 μM, 0.30 μM, 0.40 μM, 0.50 μM, 0.60 μM, 0.70 μM, 0.80 μM, or 0.90 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the RA signaling pathway activator at a concentration of 0.1 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with a low concentration of a RA signaling pathway activator.
In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one SHH pathway inhibitor at a concentration of between 0.1 μM and 0.5 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one SHH pathway inhibitor at a concentration of 0.11 μM, 0.12 μM, 0.13 μM, 0.14 μM, 0.15 μM, 0.16 μM, 0.17 μM, 0.18 μM, 0.19 μM, 0.2 μM, 0.21 μM, 0.22 μM, 0.23 μM, or 0.24 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one SHH pathway inhibitor at a concentration of 0.26 μM, 0.27 μM, 0.28 μM, 0.29 μM, 0.30 μM, 0.31 μM, 0.32 μM, 0.33 μM, 0.34 μM, 0.35 μM, 0.36 μM, 0.37 μM, 0.38 μM, 0.39 μM, 0.40 μM, 0.41 μM, 0.42 μM, 0.43 μM, 0.44 μM, 0.45 μM, 0.46 μM, 0.47 μM, 0.48 μM, or 0.49 μM. In some embodiments, the Pdx1+, NKX6-1+ pancreatic progenitor cells are contacted with the at least one SHH pathway inhibitor at a concentration of 0.25 μM.
Generally, the population of cells is maintained in a suitable culture medium for a period of time sufficient to induce the differentiation of at least one of the Pdx1+, NKX6-1+ pancreatic progenitor cells in the population into an endocrine cell. An exemplary culture medium is shown in Table 2.
In some embodiments, BE5 media can be used as a suitable culture medium for differentiating Pdx1+, NKX6-1+ pancreatic progenitor cells into endocrine cells.
In some embodiments, conditions that promote cell clustering comprise a suspension culture. In some embodiments, the period of time is at least 5 days. In some embodiments, the period of time is between 5 days and 7 days. In some embodiments, the period of time is at least 7 days. In some embodiments, the suspension culture is replenished every day (e.g., with maturation factors).
In some embodiments, at least 15% of the Pdx1+, NKX6-1+ pancreatic progenitor cells in the population are induced to differentiate into endocrine cells.
In some embodiments, at least 50% of the Pdx1+, NKX6-1+ pancreatic progenitor cells in the population are induced to differentiate into endocrine cells.
In some embodiments, at least 99% of the Pdx1+, NKX6-1+ pancreatic progenitor cells in the population are induced to differentiate into endocrine cells. In some embodiments three classes of CHGA+ endocrine cells form in Stage 5 and/or Stage 6 of a differentiation protocol. The three classes of CHGA+ endocrine cells may include SC-β cells, SC-α cells, and SC-EC cells. In some embodiments, non-endocrine cells (e.g., SOX9+ non-endocrine cells) form in Stage 5 and/or Stage 6 of a differentiation protocol.
In some aspects of the disclosure, the endocrine cells formed during Stage 5 of the differentiation protocol resemble SC-β cells. In some embodiments, the endocrine cells express at least one of the following: INS, NKX6.1, and ISL1, among other beta cell markers. In some aspects, the endocrine cells are insulin-positive endocrine cells that may mature into SC-β cells. In some embodiments, the SC-β cells express INS, NKX6.1, ISL1, PAX4, and PDX1.
In some aspects of the disclosure, endocrine cells formed during Stage 5 of the differentiation protocol resemble SC-EC cells. In some embodiments, the endocrine cells express at least one of the following: CHGA, TPH1, LMX1A, and SLC18A1. In some embodiments, the SC-EC cells express TPH1, LMX1A, SLC18A1, and FEV. In some embodiments, the SC-EC cells do not express INS and PDX1.
In some aspects of the disclosure, endocrine cells formed during Stage 5 of the differentiation protocol resemble alpha-like cells (e.g., polyhormonal cells). In some embodiments, the endocrine cells express at least one of the following: GCG, ARX, IRX2, and INS. In some embodiments, the SC-α cells express GCG, ARX, IRX2, CD36, and ISL1.
In some embodiments, stem cell-derived cells can be obtained at Stage 6 of a differentiation protocol by culturing endocrine cells in an exemplary suitable culture medium. In some embodiments, S3 media can be used as a suitable culture medium for maturing endocrine cells into stem cell-derived cells.
In some embodiments, stem cell-derived cells can be obtained at Stage 6 of a differentiation protocol by culturing endocrine cells in an exemplary suitable culture medium with at least two maturation factors comprising i) a TGF-β signaling pathway inhibitor, and ii) a thyroid hormone signaling pathway activator, to induce the differentiation or maturation of at least one endocrine cell in the population into a stem cell-derived cell. In some embodiments, CMRLS media can be used as a suitable culture medium for maturing endocrine cells into stem cell-derived cells. In some aspects, CMRLS media is supplemented with 10% FBS.
The disclosure contemplates the use of any TGF-β signaling pathway inhibitor that induces the differentiation of endocrine cells to mature into stem cell-derived cells. In some embodiments, the TGF-β signaling pathway comprises TGF-β receptor type I kinase signaling. In some embodiments, the TGF-β signaling pathway inhibitor comprises Alk5 inhibitor II.
The disclosure contemplates the use of any thyroid hormone signaling pathway activator that induces the differentiation of endocrine cells to mature into stem cell-derived cells. In some embodiments, the thyroid hormone signaling pathway activator comprises triiodothyronine (T3).
In some aspects of the disclosure, the stem cell-derived cells are obtained by 1) contacting primitive gut tube cells with RA and KGF, to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells; 2) contacting Pdx1+ pancreatic progenitor cells with KGF, to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells into Pdx1+, NKX6-1+ pancreatic progenitor cells; 3) contacting Pdx1+, NKX6-1+ pancreatic progenitor cells with XXI, Alk5i, T3, RA, SANT1, and Betacellulin, to induce the differentiation of at least some of the Pdx1+, NKX6-1+ pancreatic progenitor cells into endocrine cells; and contacting the endocrine cells with Alk5i and T3, to induce the differentiation of at least some of the endocrine cells into stem cell-derived cells.
In some aspects of the disclosure, the stem cell-derived cells are obtained by 1) contacting primitive gut tube cells with RA and LDN193189, to induce the differentiation of at least some of the primitive gut tube cells into Pdx1+ pancreatic progenitor cells; 2) contacting Pdx1+ pancreatic progenitor cells with RA and LDN193189, to induce the differentiation of at least some of the Pdx1+ pancreatic progenitor cells into Pdx1+, NKX6-1+ pancreatic progenitor cells; 3) contacting Pdx1+, NKX6-1+ pancreatic progenitor cells with XXI, Alk5i, T3, RA, SANT1, and Betacellulin, to induce the differentiation of at least some of the Pdx1+, NKX6-1+ pancreatic progenitor cells into endocrine cells; and contacting the endocrine cells with Alk5i and T3, to induce the differentiation of at least some of the endocrine cells into stem cell-derived cells.
In some embodiments stem cell-derived cells are purified using dissociation (e.g., enzymatic dissociation) followed by re-aggregation. In some aspects, the cells are enzymatically dissociated after Stage 5. In some embodiments, re-aggregation results in compartmentalization of endocrine cell populations into regions of like cells within stem cell-derived islets. In some embodiments, a population of differentiated cells is enriched for a specific type of stem cell-derived cells (e.g., SC-β cells, SC-α cells, or SC-EC cells).
Transcriptional Profiling of Stages of a Differentiation Protocol
In some aspects of the disclosure, single-cell sequencing (e.g., high throughput single-cell RNA sequencing) is used to provide a detailed characterization of the full transcriptomes of all cell populations produced using an in vitro differentiation protocol (e.g., an in vitro beta cell differentiation protocol). In some embodiments, specific genes are identified as enriching a single population of cells or combination of cells. In some aspects single-cell sequencing is performed at all stages of an in vitro differentiation protocol.
In some embodiments, sequencing is performed from the end of Stage 3 through the end of Stage 6 of a differentiation protocol (e.g., a beta cell differentiation protocol). In some aspects individual populations of cells are identified at the different stages. For example, progenitors are identified in Stages 3 and 4; three types of endocrine cells are identified in Stages 4, 5, and 6; and one type of non-endocrine cell is identified in Stages 5 and 6.
In some aspects, progenitors identified in Stage 3 of the differentiation protocol are replicating pancreatic progenitors (e.g., Pdx1+ pancreatic progenitors). In some aspects, progenitors identified in Stage 4 of the differentiation protocol include Pdx1+, NKX6-1 pancreatic progenitors. In some aspects, endocrine cells identified in Stage 4 of the differentiation protocol are alpha-like cells (e.g., SC-alpha cells). In some aspects, endocrine cells identified at Stages 5 and 6 of the differentiation protocol are CHGA+ endocrine cells. In certain aspects, the CHGA+ endocrine cells include SC-beta cells expressing INS, NKX6.1, ISL1, and other beta cell markers; alpha-like cells expressing GCG, ARX, IRX2, and INS; and SC-EC cells expressing CHGA, TPH1, LMX1A, SLC18A1. In some aspects, non-endocrine cells identified at Stages 5 and 6 of the differentiation protocol are SOX9+ non-endocrine cells. In some embodiments, the differentiation protocol produces subpopulations of cells, including: SST+/HHEX+ cells at Stages 4, 5, and 6; FOXJ1+ cells at Stages 5 and 6; FEV+/PAX4+ cells at Stage 5; PHOX2A+ cells at Stages 5 and 6; GAP43+ cells at Stage 6; and ONECUT3+ cells at Stage 6.
In some aspects of the disclosure, at the completion of the differentiation protocol (e.g., after Stage 6), clusters are formed. In some embodiments the clusters comprise one or more cell types. In some aspects the clusters are screened to identify the various cells included within the cluster. In some embodiments, the clusters are screened using single-cell sequencing (e.g., high throughput single-cell RNA sequencing) to identify the cells located with the clusters. In some aspects the clusters comprise one or more of SC-β cells, poly-hormonal cells (e.g., SC-α cells), and SC-EC cells.
In some embodiments, the RNA sequencing results of the individual populations of cells (e.g., SC-β cells, SC-α cells, SC-EC cells, etc.) at different time points (e.g., Stage 3, Stage 4, Stage 5, or Stage 6) are used to identify genes whose expression is enriched within each individual population. In some embodiments, an enrichment score is calculated for each gene in the individual populations. For example, an enrichment score may be calculated to identify genes that are specifically enriched in a given population at a specific time point during differentiation. An enrichment score compares the expression level and the number of cells that express a gene, comparing all cells that are part of a given cluster with all cells that are not within the cluster. Methods for calculating gene enrichment are described by Zeisel et al. (Cell 2018), which is incorporated herein by reference in its entirety. For example, an enrichment score (Ei,j) for gene i and cluster j, is calculated as follows:
where fi,j is the fraction of non-zero expression values in the cluster and fi,j is the fraction of non-zero expression values for cells not in the cluster. Similarly, is the mean expression in the cluster and ii,j is the mean expression for cells not in the cluster. Small constants ε1=0.1 and ε2=0.01 are added to prevent the enrichment score from going to infinity as the mean or non-zero fractions go to zero. After calculating the enrichment score the top genes and transcriptions factors may be identified for each population. In some embodiments the top 10, 15, 20, 25, 30, or 35 (overall) genes with the highest enrichment scores for each population are selected. In some embodiments the top 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 transcription factors with the highest enrichment scores for each population are selected.
In some embodiments, SC-β cells at Stage 5 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of NPTX2, SLC30A8, ACVR1C, EPAS1, TMCC3, CALB2, PCDH7, CHODL, NEFM, ITGA1, CXCL12, ISL1, G6PC2, ERO1B, SLC17A6, PCP4, PLXNA2, GAP43, RAB29, ASPH, INS, NEFL, SYNPO, VLDLR, and LRFN2. In some embodiments, SC-β cells at Stage 5 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of EPAS1, ISL1, OTP, MAFA, NR3C1, EBF1, TSHZ1, MAFB, FOXO1, and PAX6. In some embodiments, SC-β cells at Stage 6 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of IAPP, PCDH7, PCP4, ASB9, NEFM, NPTX2, PRPH, TBX3, ITGA1, ACVR1C, INS, ERO1B, CALB2, G6PC2, BACE2, CCSER1, EDARADD, PLXNA2, EPAS1, LZTS1, ERMN, TMEM196, CRTAC1, LRFN2, and NTNG2. In some embodiments, SC-β cells at Stage 6 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of TBX3, EPAS1, ISL1, HOPX, PAX4, PDX1, RXRG, BNC2, POU2F2, and ONECUT2. In some embodiments SC-β cells are identified as expressing at least one of INS, NKX6.1, PDX1, ISL1, ERO1B, and PAX4. In some aspects SC-β cells express ISL1 and ERO1B.
In some embodiments, SC-α cells at Stage 5 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of ARX, GCG, PYY, TTR, PPY, AGT, DPP4, HMP19, TMEM236, C2CD4B, SLC7A14, NPW, ALDH1A1, GAST, AKAP12, UCN3, FRRS1L, QPCT, VAT1L, ISL1, C2CD4A, IRX2, PLPPRS, IRX1, and ETV1. In some embodiments, SC-α cells at Stage 5 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of ARX, ISL1, IRX2, IRX1, ETV1, PAX6, LHX1, JUNB, POU3F2, and HOXB2. In some embodiments, SC-α cells at Stage 6 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of ARX, GCG, DPP4, PPY, IQGAP2, AGT, SERPIND1, GC, PYY, SERPINE2, HMP19, TMEM45B, CRH, ETV1, LOXL4, SERPINI1, VIM, C5orf38, GRIN3A, SPTSSB, SSTR2, LDB2, TMEM236, BTBD11, and LPAR1. In some embodiments, SC-α cells at Stage 6 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of ARX, ETV1, IRX1, JUNB, IRX2, POU6F2, GLI3, POU3F2, FOSB, and EGR4. In some embodiments SC-α cells are identified as expressing at least one of GCG, ARX, IRX2, CD36, and ISL1. In some aspects SC-α cells express ARX, GCG, and IRX2.
In some embodiments, SC-EC cells at Stage 5 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of COL5A2, CBLN1, TPH1, STC1, ADRA2A, MME, B3GAT1, CRYBA2, DNAJC12, MGLL, PTHLH, PRPS2, GDF6, ZPLD1, OVOS2, FABP3, CNTNAP2, PALM2, NEUROD4, FXYD2, IFI6, SLC18A1, RASGRP1, LMX1A, and RTN4RL2. In some embodiments, SC-EC cells at Stage 5 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of NEUROD4, LMX1A, FEV, NROB1, ZBTB7C, ASCL2, NFKBIZ, MNX1, MAFB, and TRPS1. In some embodiments, SC-EC cells at Stage 6 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of COL5A2, SLC18A1, TPH1, CBLN1, MME, MGLL, STC1, OVOS2, SLITRK1, PLDS, STAC, FEV, GPC4, FATE1, BRINP3, TAC1, RASGRP1, KCNS3, CXCL14, ADH6, LMX1A, DNAJC12, GRIA4, PRPS2, and FAM134B. In some embodiments, SC-EC cells at Stage 6 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of FEV, LMX1A, NEUROD4, SIX2, ASCL1, NFATC2, MNX1, NKX2-2, CASZ1, and ETS2. In some embodiments SC-EC cells are identified as expressing at least one of TPH1, SLC18A1, LMX1A, and PAX4. In some aspects SC-EC cells express LMX1 and TPH1.
In some embodiments, non-endocrine cells at Stage 5 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of CALB1, COL9A3, CYR61, TYMS, SOX3, ADGRG6, PCLAF, RIPPLY3, GMNN, CTGF, PLPP2, MYBL2, PHLDA3, CENPU, ID3, TK1, VCAN, ADAMTS18, C5, AURKB, ID1, UBE2C, HMGB2, WFDC2, and DDB2. In some embodiments, non-endocrine cells at Stage 5 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of SOX3, MYBL2, ID3, ID1, HMGA2, FOXM1, FOSB, FOS, HES4, and EGR2. In some embodiments, non-endocrine cells at Stage 6 of the differentiation protocol comprise one or more enriched genes selected from the group consisting of FN1, UPK1B, ANXA2, LYZ, IFITM3, FRZB, ZFP36L1, TACSTD2, MTTP, CPB1, CLPS, SPIB, SPINK1, NTS, NOTCH2, GFRA3, CLDN6, SPARC, CNN2, EFEMP1, CPA2, AHNAK, LYPD6B, SLC4A4, and TTYH1. In some embodiments, non-endocrine cells at Stage 6 of the differentiation protocol comprise one or more enriched transcription factors selected from the group consisting of SPIB, TEAD2, TGIF1, TCF7L1, PTF1A, FOSL2, SOX21, KLF5, SOX2, and MECOM.
In some embodiments, the one or more enriched genes identified herein and in
In some embodiments, a population of differentiated cells is enriched for a specific type of stem cell-derived cells (e.g., SC-β cells, SC-α cells, or SC-EC cells). In some aspects, a population of differentiated cells is enriched for SC-β cells, SC-α cells, or SC-EC cells. In some aspects, a population of differentiated cells is enriched for SC-β cells having ITGA1 (CD49a) as an SC-β cell surface marker. In some embodiments, anti-CD49a staining and magnetic microbeads are used to sort and isolate SC-β cells from a population of differentiated cells. The isolated SC-β cells form enriched clusters or islets containing up to 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% SC-β cells. In some aspects the clusters comprise fewer than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, or 2% SC-EC cells.
In some embodiments, the differentiation of a population of cells to stem cell-derived cells is directed or manipulated by targeting specific surface markers. For example, the differentiation process may be directed such that the resulting population of stem cell-derived cells is predominantly one cell type, such as SC-β cells. In some aspects, the surface markers to be targeted are one or more enriched genes and/or transcription factors identified using RNA sequencing as described herein. In some aspects, the surface markers to be targeted are one or more enriched genes and/or transcription factors identified in
In some aspects a known essential factor may be inhibited or knocked-out, thereby inhibiting development of a specific cell type (e.g., SC-β cells, SC-α cells, SC-EC cells). In other aspects a known essential factor may be activated thereby increasing cell development (e.g., SC-β cells, SC-α cells, SC-EC cells). In some embodiments the targeting of the essential factor, either to inhibit or activate, occurs using any gene editing tool known to those of skill in the art (e.g., TALENS, CRISPR, etc.). In some embodiments tumor suppressors (e.g., RB1 and/or NF2) may be knocked out or inhibited thereby resulting in uncontrolled growth of stem cells and/or progenitors, and the failure of cells to differentiate.
In certain aspects, an increased population of SC-β cells is generated by inhibiting development of SC-EC cells and increasing development of SC-β cells. For example, SC-EC cell development or production is inhibited by disrupting LMX1A, an enriched transcription factor of SC-EC cells. LMX1A may be disrupted by either knocking down LMX1A or knocking out LMX1A (e.g., using CRISPR). By disrupting SC-EC cell production during differentiation, the resulting population of differentiated cells will exhibit an increased yield of SC-β cells. In another example, PDX1, NEUROG3, and INSM1 are transcription factors known to be essential for SC-β cell development. By targeting one or more of these factors (e.g., modulating expression of one of the essential factors) SC-β cell development can be modulated.
In some embodiments, one or more transcription factors may be identified as controlling cell fate during a differentiation protocol. For example, PAX4 and ARX are example regulators of SC-β cell and SC-α cell differentiation. The regulators control the fate of the differentiated cells. In some aspects a regulator may be targeted using gene editing (e.g., CRISPR) to modulate expression of the regulator and thereby control the fate of the differentiation process. In some aspects a first regulator may be knocked out or inhibited, while a second regulator may be activated. In some aspects ARX is inhibited or knocked-out and/or PAX4 is activated thereby causing a population of differentiating cells to form SC-β cells. In other aspects ARX is activated and/or PAX is knocked out or inhibited thereby causing a population of differentiating cells to form SC-α cells.
Stem Cell-Derived Enterochromaffin Cells
In some aspects of the disclosure, a stem cell-derived enterochromaffin cell (SC-EC) is provided. The SC-EC cells disclosed herein share many distinguishing features of native EC cells, but are different in certain aspects. In some embodiments, the SC-EC cell is non-native, i.e., non-naturally occurring, non-endogenous cell. As used herein, “non-native” means that the SC-EC cells are markedly different in certain aspects from EC cells which exist in nature, i.e., native EC cells. It should be appreciated, however, that these marked differences may result in the SC-EC cells exhibiting certain differences, but the SC-EC cells may still behave in a similar manner to native EC cells with certain functions altered (e.g., improved) compared to the native EC cells.
The SC-EC cells of the disclosure share many characteristic features of EC cells which are important for normal EC cell function. In some embodiments, the SC-EC cell is capable of producing serotonin (5-HT). In some embodiments, the SC-EC cell releases serotonin upon depolarization with KCl. In certain aspects, the SC-EC cell releases serotonin in vitro upon depolarization with KCl. The SC-EC cells do not release serotonin upon stimulation with high glucose.
In some embodiments, the SC-EC cells express one or more of the following genes: THP1, SLC19A1, LMX1A, PAX4, DDC, TRPA1, SCN3A, ADRa2A, FEV, TAC1, and CXCL14. In some embodiments, the SC-EC cells co-express the genes TPH1, LMX1A, and SLC19A1. In some embodiments, the SC-EC cells co-express TPH1 and LMX1A. In some aspects, the SC-EC cells do not express one or more of the following markers: G6PC2, NPTX2, ISL1, PDX, and ERO1B.
The SC-EC cells are differentiated in vitro from any starting cell as the invention is not intended to be limited by the starting cell from which the SC-EC cells are derived. Exemplary starting cells include, without limitation, endocrine cells or any precursor thereof such as a NKX6-1+ pancreatic progenitor cell, a Pdx1+ pancreatic progenitor cell, and a pluripotent stem cell, an embryonic stem cell, and induced pluripotent stem cell. In some embodiments, the SC-EC cells are differentiated in vitro from a reprogrammed cell, a partially reprogrammed cell (i.e., a somatic cell, e.g., a fibroblast which has been partially reprogrammed such that it exists in an intermediate state between an induced pluripotency cell and the somatic cell from which it has been derived), a transdifferentiated cell. In some embodiments, the SC-EC cells disclosed herein can be differentiated in vitro from an endocrine cell or a precursor thereof. In some embodiments, the SC-EC cell is differentiated in vitro from a precursor selected from the group consisting of a NKX6-1+ pancreatic progenitor cell, a Pdx1+ pancreatic progenitor cell, and a pluripotent stem cell. In some embodiments, the pluripotent stem cell is selected from the group consisting of an embryonic stem cell and induced pluripotent stem cell. In some embodiments, the SC-EC cell or the pluripotent stem cell from which the SC-EC cell is derived is human. In some embodiments, the SC-EC cell is human.
In some embodiments, the SC-EC cell is not genetically modified. In some embodiments, the SC-EC cell obtains the features it shares in common with native EC cells in the absence of a genetic modification of cells. In some embodiments, the SC-EC cell is genetically modified.
In some aspects, the disclosure provides a cell line comprising a SC-EC cell described herein. In some aspects, the disclosure provides an SC-islet comprising SC-EC cells described herein.
In some embodiments, the cells described herein, e.g. a population of SC-EC cells are transplantable, e.g., a population of SC-EC cells can be administered to a subject. In some embodiments, the subject who is administered a population of SC-EC cells is the same subject from whom a pluripotent stem cell used to differentiate into a SC-EC cell was obtained (e.g. for autologous cell therapy). In some embodiments, the subject is a different subject. In some embodiments, a subject is suffering from an intestinal disorder such as intestinal inflammation, or is a normal subject. For example, the cells for transplantation (e.g. a composition comprising a population of SC-EC cells) can be a form suitable for transplantation, e.g., organ transplantation.
The method can further include administering the cells to a subject in need thereof, e.g., a mammalian subject, e.g., a human subject. The source of the cells can be a mammal, preferably a human. The source or recipient of the cells can also be a non-human subject, e.g., an animal model. The term “mammal” includes organisms, which include mice, rats, cows, sheep, pigs, rabbits, goats, horses, monkeys, dogs, cats, and preferably humans. Likewise, transplantable cells can be obtained from any of these organisms, including a non-human transgenic organism. In one embodiment, the transplantable cells are genetically engineered, e.g., the cells include an exogenous gene or have been genetically engineered to inactivate or alter an endogenous gene.
A composition comprising a population of SC-EC cells can be administered to a subject using an implantable device. Implantable devices and related technology are known in the art and are useful as delivery systems where a continuous, or timed-release delivery of compounds or compositions delineated herein is desired.
Additionally, the implantable device delivery system is useful for targeting specific points of compound or composition delivery (e.g., localized sites, organs). Negrin et al., Biomaterials, 22(6):563 (2001). Timed-release technology involving alternate delivery methods can also be used in this invention. For example, timed-release formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymeric, liposomal) can also be used for delivery of the compounds and compositions delineated herein.
For administration to a subject, a cell population produced by the methods as disclosed herein, e.g. a population of SC-EC cells can be administered to a subject, for example in pharmaceutically acceptable compositions. These pharmaceutically acceptable compositions comprise a therapeutically-effective amount of a population of SC-EC cells as described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
As described in detail below, the pharmaceutical compositions of the present invention can be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), lozenges, dragees, capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8) transmucosally; or (9) nasally. Additionally, compounds can be implanted into a patient or injected using a drug delivery system. See, for example, Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. “Controlled Release of Pesticides and Pharmaceuticals” (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; and U.S. Pat. No. 35 3,270,960.
As used here, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used here, the term “pharmaceutically-acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. The terms such as “excipient”, “carrier”, “pharmaceutically acceptable carrier” or the like are used interchangeably herein.
The phrase “therapeutically-effective amount” as used herein in respect to a population of cells means that amount of relevant cells in a population of cells, e.g., SC-EC cells, or composition comprising SC-EC cells of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment. For example, an amount of a population of SC-EC cells administered to a subject that is sufficient to produce a statistically significant, measurable change in at least one symptom of an intestinal or gastrointestinal tract disease or disorder (e.g., intestinal inflammation, irritable bowel disease, and the like). Determination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, a therapeutically effective amount can vary with the subject's history, age, condition, sex, as well as the severity and type of the medical condition in the subject, and administration of other pharmaceutically active agents.
As used herein, the term “administer” refers to the placement of a composition into a subject by a method or route which results in at least partial localization of the composition at a desired site such that desired effect is produced. A compound or composition described herein can be administered by any appropriate route known in the art including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration.
Exemplary modes of administration include, but are not limited to, injection, infusion, instillation, inhalation, or ingestion. “Injection” includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the compositions are administered by intravenous infusion or injection.
By “treatment,” “prevention,” or “amelioration” of a disease or disorder is meant delaying or preventing the onset of such a disease or disorder, reversing, alleviating, ameliorating, inhibiting, slowing down or stopping the progression, aggravation or deterioration of the progression or severity of a condition associated with such a disease or disorder. In one embodiment, the symptoms of a disease or disorder are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
In certain embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “patient” and “subject” are used interchangeably herein. Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples.
Toxicity and therapeutic efficacy of administration of a compositions comprising a population of SC-EC cells can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). Compositions comprising a population of SC-EC cells that exhibit large therapeutic indices are preferred.
The amount of a composition comprising a population of SC-EC cells can be tested using several well-established animal models.
In some embodiments, data obtained from the cell culture assays and in animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
The therapeutically effective dose of a composition comprising a population of SC-EC cells can also be estimated initially from cell culture assays. Alternatively, the effects of any particular dosage can be monitored by a suitable bioassay.
With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to the SC-EC cells. The desired dose can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms. In some embodiments, administration is chronic, e.g., one or more doses daily over a period of weeks or months. Examples of dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.
In another aspect of the invention, the methods provide use of an isolated population of SC-EC cells as disclosed herein. In one embodiment of the invention, an isolated population of SC-EC cells as disclosed herein may be used for the production of a pharmaceutical composition, for the use in transplantation into subjects in need of treatment.
One embodiment of the invention relates to a method of treating an intestinal disorder or disease in a subject comprising administering an effective amount of a composition comprising a population of SC-EC cells as disclosed herein to a subject with an intestinal disorder or disease. In a further embodiment, the invention provides a method for treating an intestinal disorder or disease, comprising administering a composition comprising a population of SC-EC cells as disclosed herein to a subject that has, or has increased risk of developing an intestinal disorder or disease in an effective amount sufficient to secrete serotonin.
In vitro differentiation of human stem cells can produce beta cells, the insulin-secreting cell type whose loss underlies Type 1 Diabetes. As a step towards mastery of this process, transcriptional profiling of >100,000 individual cells sampled during in vitro beta cell differentiation was reported and the cell populations that emerge were described. Populations corresponding to beta cells, alpha-like poly-hormonal cells, non-endocrine cells that resemble pancreatic exocrine cells and a previously unreported population resembling enterochromaffin cells were resolved. It was shown that the beta and alpha-like cells are largely stable for weeks in culture without exogenous growth factors and that gene expression changes associated with in vivo beta cell maturation are recapitulated in vitro. The transcriptomes of stem-cell derived enterochromaffin cells were described and it was shown that they are capable of synthesizing and secreting serotonin in vitro. To remove exocrine cells, a scalable dissociation and re-aggregation technique was characterized that efficiently selects for endocrine cell types. Finally, a high-resolution sequencing time course was used to characterize gene expression dynamics during human pancreatic endocrine induction from which a lineage model of in vitro beta cell differentiation was presented. The results described herein provides a deeper perspective on the current state of human stem cell differentiation and is a jumping point for future endeavors in in vitro differentiation of pancreatic islet cells and their application in regenerative medicine.
In the SC-beta protocol, human pluripotent stem cells grown in 3D clusters are differentiated towards beta cells via 6 stages with stage specific inducing factors (distinct medias and growth factors). Progress and efficiency during these stages are measured using immunofluorescence microscopy and flow cytometry (
As described herein, single cell RNA sequencing and computational analysis methods are applied to generate a deep understanding of the in vitro beta cell differentiation process. The goal is to first define the cell types that emerge at different stages of pancreatic differentiation through their gene expression profiles and to subsequently characterize their lineage origins and maturation trajectories. This cell by cell description defines the process of in vitro beta cell differentiation with precision and will guide further protocol engineering. These are critical steps in advancing directed differentiation of stem cells towards a treatment for diabetes.
SC-beta differentiation produces 4 major cell populations 40,444 cells were sequenced using inDrops, sampled from the ends of Stages 3 through 6 from two differentiations done with two modified protocols. The first objective was to define cell populations using their full transcriptome rather than a preselected panel of antibodies for a few genes. Via systematic signaling factor subtraction (data not shown) it was discovered that significant modifications of the signaling factors yielded similar populations as measured by flow cytometry but in different ratios (
Distinct populations of progenitors (in Stages 3 & 4), three types of endocrine cells (Stages 4, 5 & 6) and non-endocrine cells (Stages 5 & 6) were identified. In both protocols, it is shown that the cells at Stage 3 comprise a single population of replicating pancreatic progenitors (PDX1+,
Although the two protocol variants tested showed the expected large differences in cell type ratios (
The key properties of SC-beta cells are their glucose responsiveness and their transcriptional similarity to endogenous human beta cells. These properties were characterized across several weeks of Stage 6, during which cells were cultured in serum-free media without exogenous signaling factors (protocol v8). Single cell RNA sequencing, in vitro glucose stimulated insulin secretion (GSIS) and flow cytometry was carried out across several weeks of Stage 6, sampling at weekly intervals from three independent differentiations (
SC-beta clusters acquire the ability to secrete insulin in response to glucose after approximately 2 weeks in Stage 6 culture and retain this ability for another ˜4 weeks (
With parallel single-cell sequencing measurements, it was observed that the transcriptomes of each populations are highly correlated across time points. In each flask and time point, endocrine populations comprising SC-beta cells (expressing INS, NKX6.1, PDX1, ISL1, PAX4), poly-hormonal cells (GCG, INS, ARX, ISL1), and SC-EC cells (TPH1, SLC18A1, LMX1A, PAX4) as well as CHGA-non-endocrine cells were identified (
Consistent with their capacity to secrete insulin in response to glucose, it was observed that SC-beta cells express key genes involved in the regulation of insulin gene expression, protein synthesis, packaging and secretion (
Finally, it was sought to more exactly describe the refinements in SC-beta gene expression that occurred during this time course. First, it was determined that further clustering of SC-beta cells revealed a single population lacking branches or distinct subpopulations (
Poly-Hormonal Cells (INS+/GCG+) are Immature Alpha Cells.
Poly-hormonal cells, expressing both insulin and glucagon genes, have been reported in several in vitro pancreatic differentiation protocols. It was demonstrated that poly-hormonal cells represent cells whose global transcriptomes match islet alpha cells, but erroneously express insulin. This erroneous expression of insulin is corrected during the course of Stage 6 (
A broad survey identified a population of non-islet endocrine cells that expresses TPH1, NKX6.1 and low levels insulin, but differ from SC-beta cells by lacking expression of beta-cell markers G6PC2, NPTX2, ISL1 and PDX1 (
Although serotonin production via TPH1 has been reported in human beta cells [Almaca 2016], expression of TPH1 was not observed in either in vivo or in vitro beta populations [Baron 2016, Xin 2016; Segerstolpe 2016; Muraro 2016; Enge 2017]. Other studies have shown that serotonin production may occur in beta cells in an age- or context-dependent manner, which may not be captured in these single cell RNA-sequencing data [Almaca 2016; Goyvaerts 2016; Ohta 2011]. While expression of TPH1 and other EC markers was not found in RNA-Seq datasets from normal islets, a signal of the induction of a serotonin/EC program in perturbed mouse beta cells was identified from recently published data [Lu 2018]. Specifically, 25 weeks after a beta-cell specific knockout of the Polycomb repressive complex 2 (PRC2) component EED, upregulation of Tph1, Lmx1a, Slc18a1 and Trpa1 and downregulation of beta cell identity genes was seen (
Non-Endocrine Cells Differentiate into Acinar and Ductal Cells
Some cells do not adopt an endocrine fate during Stages 4 and 5 (
Given the concerns of transplanting non-endocrine cells with the potential to proliferate, scalable methods for enrichment of post-mitotic endocrine cells were sought. Single-cell dissociation followed by controlled re-aggregation has been used to purify endocrine cells from neonatal pancreas [Britt 1981] and in vitro derived beta-like cell preparations [Agulnick 2015]. Recent methods [Agulnick 2015; Hilderink 2015; Ramachandran 2014; Spijker 2013; Zuellig 2017] for re-aggregation of endocrine cells utilize micro-patterned surfaces, hanging droplets, soluble extracellular matrix factors or RHO kinase inhibition to increase efficiency. It was discovered that enzymatic dissociation followed by re-aggregation after Stage 5 could be applied to the SC-beta protocol (
To generate insights from single cell RNA sequencing that will translate to fully controlling the process of SC-beta differentiation, the formation dynamics of the major cell populations identified must be understood. In particular, the similarity in transcriptional programs and emergence timing of SC-beta and SC-EC cells make the transition states during their specification especially interesting. Single cell sequencing can reconstruct developmental trajectories both from single snapshots or sequential samplings [Tusi 2018; Schiebinger 2017]. While multiple new cell types are present at the end of Stage 5 that were absent in Stage 4, the transition states are not captured by either dataset. To bridge this gap, ˜45,000 cells were chosen to be sequenced at daily intervals throughout the course of Stage 5 for two independent differentiations.
From a global perspective, individual cells in this dataset form a continuum that connects the starting populations of Stage 5 (day 0) to the populations present at the end. The two extremes of this continuum are cells that have become endocrine (CHGA+) and those that have not (initially progenitors, later non-endocrine cells). NEUROG3, a transiently-expressed master regulator of in vivo endocrine induction, is expressed by cells bridging non-endocrine and endocrine cells within this continuum (
At the conclusion of Stage 4, progenitors form a single population displaying gene expression heterogeneity in the form of a gradient with one end SOX2+, FRZB+, and PDX1low and the other NKX6.1+, PTF1A+, and PDX1high (
As endocrine induction progresses in S5, it yields primarily SC-beta and SC-EC fates. The earliest emergence of these two cell types is on S5D3, which represents the second branching point in S5. To further explore this bifurcation, cells from the SC-beta, SC-EC and endocrine induction clusters were selected and diffusion pseudotime analysis (PDT,
From this high-resolution time course of Stage 5, a model was built of the lineage relationship of cell types produced by SC-beta differentiation (
Beta cells are front-runners in the field of regenerative medicine, promising to replace cells lost in disease and provide models for drug discovery. Because directed differentiation protocols for beta cells and other cell types produce additional cell types beyond the desired population, single-cell RNA sequencing is uniquely suited for disentangling cell type identities and origins. In this study, single cell RNA sequencing experiments were used to comprehensively characterize the cell types formed during SC-beta differentiation and their transcriptional trajectories. By using an unbiased approach, expected populations can be further described, as well as identify unexpected populations.
The stepwise differentiation of millions of human cells in a nearly synchronous fashion provides an unprecedented opportunity to examine each cell type produced by SC-beta differentiation and evaluate their relevance to the goals of stem cell therapy. It was shown that functional SC-beta cells which are responsive to glucose in vitro constitute a single, transcriptionally stable population under extended culture without signaling effectors. Among the few dynamic genes within SC-beta cells during the last stage of differentiation, several genes previously characterized as markers of beta cell maturation were found. Looking beyond SC-beta cells, the identity of poly-hormonal cells has previously been obfuscated by their expression of insulin but lack of other beta cell markers. Based on transcription factor expression and global similarity, it was concluded that these poly-hormonal cells directly form as alpha-like (SC-alpha) cells that initially misexpress insulin. In the context of transplantation, these cells may improve beta cell function through local interactions or autocrine signaling within SC-islets. Finally, it was shown that progenitors that fail endocrine induction instead mature towards pancreatic exocrine cell types. These seem undesirable, both because they may replicate and because they may take up limited space within transplantation devices. To enrich for endocrine cells, a scalable re-aggregation method was described that depletes exocrine cells and enhances the glucose responsive insulin secretion of SC-beta clusters.
A surprising finding of the analysis is the existence of SC-EC cells which would have previously been classified as a progenitor on the basis of immunostaining for NKX6.1, CHGA and lack of GCG. Although SC-EC cells are closely developmentally related to SC-beta cells, they are a distinct cell type formed from a late bifurcation in the endocrine induction process. In vivo, enterochromaffin cells have not been observed in single cell studies of mouse and human islets [Baron 2016, Xin 2016; Segerstolpe 2016; Muraro 2016; Enge 2017]. Enterochromaffin cells can likely arise in the human pancreas. For instance, several cases of primary pancreatic serotonin-producing carcinoid tumors have been reported [Tsoukalas 2017; Kawamoto 2011], suggesting the possibility of a scarce population of pancreatic enterochromaffin cells. Evidence was also presented in a published dataset that PRC2 knockout in beta cells eventually induces downregulation of beta cell markers and upregulation of enterochromaffin markers in adult mouse islets [Lu 2018], possibly a signal of beta to enterochromaffin transdifferentiation. This supports the idea that enterochromaffin cells are a rare alternate pancreatic fate that is ordinarily suppressed.
This characterization provides a resource for further refining protocols for beta cell differentiation. For instance, hypotheses on controlling cell fate through activation or inhibition of signaling pathways may be guided by the differential receptor expression across cell types, as well as inferred signaling activities based on gene expression. Furthermore, studies of in vitro endocrine induction may yield insights that translate to its in vivo counterpart
Overall, a comprehensive and detailed analysis of a stem-cell derived product developed in the pursuit of human stem cell therapy was provided. This type of high-resolution expression profiling is necessary to confidently assess the identities of in vitro produced cells on the road towards successful and safe therapies.
This Example both re-presents certain data from Example 1 and provides additional data.
In vitro differentiation of human stem cells can produce pancreatic beta cells, the insulin-secreting cell type whose loss underlies Type 1 Diabetes. As a step toward mastery of this process, a report on transcriptional profiling of >100,000 individual cells sampled during in vitro beta cell differentiation is provided and describes the cells that emerge. Populations are resolved corresponding to beta cells, alpha-like poly-hormonal cells, non-endocrine cells that resemble pancreatic exocrine cells and a previously unreported population resembling enterochromaffin cells. It is shown that endocrine cells maintain their identity in culture without exogenous growth factors and that gene expression changes associated with in vivo beta cell maturation are recapitulated in vitro. A scalable re-aggregation technique is implemented to deplete non-endocrine cells and identify CD49a/ITGA1 as a surface marker for the beta population allowing magnetic sorting to a purity of 80%. Finally, a high-resolution sequencing time course is utilized to characterize gene expression dynamics during human pancreatic endocrine induction from which a lineage model of in vitro beta cell differentiation is developed. This study provides a deeper perspective on the current state of human stem cell differentiation and will guide future endeavors on differentiation of pancreatic islet cells and their application in regenerative medicine.
In the SC-beta protocol, human pluripotent stem cells grown in 3D clusters are differentiated with 6 stages with specific inducing factors to produce ‘SC-islets’ that contain stem cell-derived beta cells. Progress and efficiency are measured using immunofluorescence microscopy and flow cytometry (
Here a single cell RNA sequencing and computational analysis is applied to generate a deep understanding of in vitro beta cell differentiation (
SC-Islets Contain 4 Major Cell Types
40,444 cells sampled from the ends of Stages 3 through 6 from differentiations done with two modified protocols were sequenced to define cell populations using their entire transcriptomes. These two protocols use subsets of the original1 v1 Stages 3 and 4 factors and yield different populations ratios at Stage 4 (
The major populations identified (
Beyond these major populations, both protocols include a small population of SST+/HHEX+/ISL1+ cells that emerge as early as the end of Stage 4. A single population, labelled by high levels of FOXJ1+, was present in only one protocol (
Finally, Stage 6 cells produced from differentiation of embryonic stem cells (ESCs, line HUES8) were compared to induced pluripotent stem cells (iPSCs, line 1016/31) and high correlations were observed between the corresponding cell types (
SC-Beta Cells Stably Maintain Identity
The key properties of SC-beta cells are glucose responsiveness and transcriptional similarity to endogenous human beta cells. These properties were characterized across several weeks of Stage 6, using serum-free media without exogenous signaling factors (protocol v8). Single cell RNA sequencing and in vitro glucose stimulated insulin secretion (GSIS) tests were carried out across several weeks of Stage 6, sampling at weekly intervals from three differentiations (
SC-islets acquire glucose responsive insulin secretion in the first week of Stage 6 and retain this ability for another ˜4 weeks (
In parallel, whether the Stage 6 cell populations maintain their identity during extended time in culture was assessed. As in the previous dataset, SC-beta, SC-alpha, SC-EC cells and non-endocrine cells are identified (
Consistent with their glucose responsiveness, it is observed that SC-beta cells express key genes of beta cell identity15, metabolic sensing and signaling16 and insulin synthesis, packaging and secretion17. Broadly, these genes are expressed in both cadaveric islet beta cells and SC-beta cells but not in the NKX6.1+ progenitors of the later (
Finally, it is sought to describe the refinements in SC-beta gene expression that occur over time. Pseudotime analysis was applied to order the cells according to their transcriptional state and regressed gene expression using pseudotime to identify dynamic genes (
Early SC-Alpha Cells Express Insulin
Poly-hormonal cells, expressing both insulin and glucagon, have been reported in several in vitro pancreatic differentiation protocols. Beyond glucagon, these cells express many markers of islet alpha cells, but uncharacteristically express insulin. On this basis, and because expression of insulin is rectified during Stage 6 (
Stem-Cell Derived Enterochromaffin Cells
This survey identified a population of endocrine cells expressing TPH1, NKX6.1 and low levels of insulin, but lacking beta cell markers G6PC2, NPTX2, ISL1 and PDX1. It is hypothesized that these cells are stem-cell derived enterochromaffin cells (SC-EC). Enterochromaffin cells synthesize and secrete serotonin (5-HT) in the gut where they serve as chemosensors24. Their transcriptome has been characterized via single-cell sequencing of murine intestinal epithelium25 and organoids26. Compared to SC-beta cells (
Although serotonin is reportedly produced in human beta cells29, expression of TPH1 is not observed in either in vivo or in vitro beta populations5-9, nor are EC cells found in single cell profiling of the pancreas5-11. Other studies have shown that beta cells produce serotonin in age- or context-dependent manners, not explored in existing single-cell datasets29-31. However, a signal of the induction of a serotonin/EC program in perturbed mouse beta cells was identified from recently published data32, suggesting a small “distance” between the beta and EC fates. Specifically, 25 weeks after a beta-cell specific knockout of the Polycomb repressive complex 2 (PRC2) component EED, upregulation of enterochromaffin marker genes Tph1, Lmx1a, Slc18a1 and Trpa1 is noted (
Fates of Non-Endocrine Cells
Some cells do not adopt an endocrine fate during Stages 4 and 5 (
Purification of Endocrine and SC-Beta Cells
Single-cell dissociation followed by controlled re-aggregation has been used to purify endocrine cells from neonatal pancreas33 and in vitro beta cell preparations34. It was discovered that enzymatic dissociation followed by re-aggregation can be applied after Stage 5. Unlike previous methods, this approach is scalable because it does not require micro-patterned surfaces, hanging droplets or soluble extracellular matrix factors to increase efficiency. Using single-cell sequencing, flow cytometry and GSIS (
Beyond endocrine enrichment, ways of specifically enriching for SC-beta cells were explored. The analysis identifies ITGA1 (CD49a) as a novel SC-beta surface marker (
The Origin and Lineage of SC-Beta Cells
Single cell sequencing can reconstruct complex developmental trajectories both from single snapshots or sequential samplings. SC-beta and SC-EC cells are absent at the end of Stage 4 and appear during the course of Stage 5. Given shared expression of key genes (such as PAX4, NKX6-1), it was sought to determine whether these cells form separately during endocrine induction or whether one is a precursor for the other. To this end, ˜45,000 cells were sequenced at daily intervals throughout the course of Stage 5 for two independent differentiations.
From a global perspective, individual cells in this dataset form a continuum connecting Stage 5 day 0 and day 7 populations. NEUROG3, a transiently-expressed master regulator of in vivo endocrine induction, is expressed by cells bridging endocrine and non-endocrine cells within this continuum as different cell types gradually emerge (
The initiation of endocrine induction is the first major bifurcation of cells during Stage 5. On day 0, progenitors form a single heterogenous population characterized by a gradient from SOX2+, FRZB+, PDX1low to NKX6.1+, PTF1A+, PDX1high cells (
Stage 5 endocrine induction primarily yields SC-beta and SC-EC cells, with the earliest cells of these types emerging on day 3. Global clustering and manifold embedding suggest a late branching of the SC-beta and SC-EC fates. To validate this branching observation, diffusion pseudotime of all SC-beta, SC-EC and NEUROG3+ cells was computed (
Beta cells are front-runners in the field of regenerative medicine. Nonetheless, directed differentiation protocols for beta cells produce other cells alongside them. In this study, single-cell RNA sequencing experiments are used to comprehensively characterize cells formed during SC-beta differentiation.
The stepwise, synchronous differentiation of millions of cells provides an unprecedented opportunity to study human developmental processes. It is shown that SC-beta cells respond to glucose in vitro and maintain their identity under extended culture without signaling modulators. Dynamic genes include several markers of beta cell maturation. Furthermore, the identity of poly-hormonal cells has previously been controversial. It is concluded that they represent alpha-like (SC-alpha) cells that only transiently misexpress insulin. In the context of transplantation, these cells may improve beta cell function through local interactions or autocrine signaling within SC-islets. It is shown that progenitors that fail endocrine induction progress toward pancreatic exocrine cell types. These seem undesirable, as they may replicate or occupy precious space within transplantation devices. To eliminate them, a scalable re-aggregation method is described that enriches endocrine cells. Additionally, CD49a is identified as a surface marker of SC-beta cells and highly pure SC-beta clusters are generated via magnetic sorting.
An unexpected finding of this analysis is the existence of SC-EC cells in vitro. It is shown that SC-EC cells are closely related but fundamentally distinct from SC-beta cells, arising from a late bifurcation of differentiation. Given this close similarity and their expression profile for key genes (NKX6.1+/CHGA+/GCG−), these cells may be misclassified as either progenitors or bona fide beta cells when analyzed via methods using preselected groups of genes14. In vivo, enterochromaffin cells have not been observed in studies of mouse and human islets5-9. Nonetheless, extremely rare reports of primary pancreatic serotonin-producing carcinoid tumors support the existence resident pancreatic enterochromaffin cells35. Importantly, it is shown that CD49a purification depletes SC-EC cells.
This study provides a resource for future development of beta cell differentiation protocols. For instance, hypotheses on controlling cell fate by modulating signaling pathways may be guided by receptor expression patterns or inferred signaling activities. Although SC-beta cells are highly similar to cadaveric beta cells, differences remain including the lack of expression of UCN3, MAFA, and SIX3. While these genes are likely expressed after transplantation in vivo, they represent the next milestone in the pursuit of ever more mature SC-beta cells in vitro. In parallel, further milestones in characterizing SC-beta differentiation will come from single-cell measurements of proteins, epigenetics and lineage.
Overall, a comprehensive and detailed analysis is provided of a stem-cell product destined for human therapeutics. This type of high-resolution, single-cell profiling represents a necessary step on the road toward successful and safe therapies.
Cell Culture
Human pluripotent stem cell (hPSC) maintenance and differentiation was carried out as previously described1. Pluripotent stem cell lines were obtained from stocks maintained by the Melton lab or Semma Therapeutics. Lines were identified by DNA fingerprinting (Cell Line Genetics) and all lines tested negative on routine mycoplasma contamination verifications. Pluripotent stem cell lines were maintained in cluster suspension culture format using mTeSR1 (Stem Cell Technologies, 85850) in 500 mL spinner flasks (Corning, VWR) spinning at 70 rpm in an incubator at 37° C., 5% CO2 and 100% humidity. Cells were passaged every 72 hours: hPSC clusters were dissociated to single cells using Accutase (Innovative Cell Technologies; AT104-500) and light mechanical disruption, counted, and seeded at 0.5 M cells/mL in mTeSR1+10 μM Y27632 (DNSK International, DNSK-KI-15-02).
Differentiation flasks were started 72 hours after passage by removing mTeSR1 media and replacing with the protocol-appropriate media and growth factor or small molecule supplements (see
Flow Cytometry
Differentiated clusters, sampled from the suspension culture (1-2 mL), were dissociated using TrypLE Express (Gibco; Ser. No. 12/604,013) at 37° C., mechanically disrupted to form single cells, fixed using 4% PFA for 30 minutes at RT and stored in PBS at 4° C. For staining, fixed single cells were incubated in blocking buffer for 1 hour at RT, then incubated in blocking buffer with primary antibodies (1 hr at RT or overnight at 4° C.), washed three times with blocking buffer, incubated with secondary antibodies in blocking solution (1 hr at RT), washed three times and resuspended in PBS+0.5% BSA (Proliant; 68700). Blocking buffer: PBS+0.1% saponin (Sigma; 47036)+5% donkey serum (Jackson Labs; 100181-234). Stained cells were analyzed using the LSR-II, Accuri C6 (BD Biosciences) or Attune NxT (Invitrogen) flow cytometers. An example gating strategy is shown in
Immunofluorescence Microscopy
Differentiated clusters were fixed in 4% PFA for 1 hour at RT, washed and frozen in OCT and sectioned. Prior to staining, paraffin-embedded samples were treated with Histo-Clear to remove the paraffin. All slides were rehydrated via an ethanol gradient and incubated in boiling antigen retrieval reagent (10 mM sodium citrate, pH 6.0) for 30 minutes. For staining, slides were incubated in CAS block (ThermoFisher; 008120) with primary antibody overnight at 4° C., washed three time, incubated in secondary antibody for 2 hours at RT, washed, mounted in Vectashield with DAPI (Vector Laboratories; H-1200) or ProLong Diamond Antifade Mountant with DAPI, covered with coverslips and sealed with clear nail polish. Representative regions were imaged using Zeiss.Z2 with Apotome or Zeiss CellDiscoverer 7 microscopes. Images shown are representative of similar results in at least 3 biologically separate differentiations from matched or similar stages.
Antibodies
Primary antibodies (supplier; catalog number, effective dilution): rat anti-C-peptide (DHSB; GN-ID4; 1:100), mouse anti-NKX6.1 (DHSB; F55A12; 1:50), rabbit anti-CHGA (Abcam; ab15160; 1:500), rabbit anti-SLC18A1 (Sigma; HPA063797; 1:300), rabbit anti-LMX1A (Sigma; HPA030088; 1:300), sheep anti-TPH1 (EMD Millipore; AB1541; 1:100), goat anti-5-HT (Immunostar; 20079; 1:1000), rabbit anti-SOX9 (Cell Marque; AC-0284RUO; 1:500), mouse anti-glucagon (Santa Cruz Biotech.; SC-514592; 1:300).
Secondary antibodies (supplier; catalog number, all used at 1:300 dilution): anti-rat 594 (Life Tech.; A21209), anti-mouse 594 (Life Tech.; A21203), anti-mouse 647 (Life Tech.; A31571), anti-rabbit 488 (Life Tech.; A21206), anti-rabbit 594 (Life Tech.; A21209), anti-rabbit 647 (Life Tech.; A31573), anti-goat 647 (Life Tech.; A21447), anti-sheep 488 (Life Tech.; A11015), anti-rat 488 (Jackson labs.; 712-546-153), Anti-rat 405 (Abcam; ab175670).
Transplantation Studies
Transplantation of differentiated clusters was carried out as previously described1. Briefly, ˜500 IEQ human islets or ˜5×106 Stage 6 native (day 10, non-reaggregated) SC-islet clusters were transplanted under the kidney capsule of male SCID beige mice (Jackson labs) aged between 8 and 12 weeks. At the specified time after transplantation, kidneys containing grafts were dissected and fixed in 4% PFA overnight at 4° C. The fixed kidneys were embedded in paraffin and sectioned for immunofluorescence staining, which was performed as described above. All animal studies were approved by the Harvard University IACUC.
Glucose Stimulated Insulin and Serotonin Secretion
Human islets (˜400 IEQ, Prodo Laboratories) or SC-islet clusters (equivalent to ˜4×106 cells between 28 and 60 days of differentiation) were divided into four parts to collect technical triplicate and insulin/serotonin content samples. Krebs buffer (KRB) was prepared: 128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2, 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES (Life Technologies; Ser. No. 15/630,080), 0.1% BSA in deionized water. Clusters were washed twice with low-glucose (2.8 mM) KRB and were then loaded into the 24 well plate inserts (Millicell Cell Culture Insert; PIXP01250) and fasted in low-glucose KRB for 1 hr to remove residual insulin in 37° C. incubators. Clusters were washed once in low-glucose KRB, incubated in low-glucose KRB for 1 hour, and supernatant collected. Then clusters were transferred to high-glucose (20 mM) KRB for 1 hour, and supernatant collected. This sequence was repeated one additional time and clusters were washed once between high-glucose to second low-glucose incubation to remove residual glucose. Finally, clusters were incubated in KRB containing 2.8 mM glucose and 30 mM KCl (depolarization challenge) for 1 hour and then supernatant collected. Clusters were then dispersed into single cells using TrypLE Express, and cell number was counted automatically by a Vi-Cell (Beckman Coulter) to normalize insulin level by the cell number. Supernatant samples containing secreted insulin were processed using the Human Ultrasensitive Insulin ELISA (ALPCO, 80-INSHUU-E01.1) and the Serotonin ELISA (ALPCO; 17-SERHU-E01-FST).
Dynamic Perifusion Assay for Glucose Stimulated Insulin Secretion
Dynamic GSIS was performed as previously described19. Non-diabetic human islets from Prodolabs (100-250 um diameter sized 25 IEQ islets were handpicked per sample, n=3) and native or purified SC-beta clusters (100-250 m diameter sized 25 clusters were handpicked per sample, n=3), were assayed on a fully automated Perifusion System (BioRep). Chambers were sequentially perifused with 2.8 mM or 20 mM glucose, or 2.8 mM glucose with 30 mM KCL in KRB buffer at a flow rate of 100 ul/min. Chambers were first perifused with low glucose (2.8 mM) for 1 hour for fasting and then 15 minutes for low glucose incubation followed by high glucose (20 mM) challenge for 30 minutes. Samples were then perifused with low glucose for 15 minutes followed by low glucose and 30 mM KCl for 15 minutes. Insulin concentrations in the supernatant were determined using an Ultrasensitive Insulin ELISA kit (Alpco; 80-INSHUU). The insulin secretion levels were normalized by total cell number (uIU/mL/1000 cells).
Re-Aggregation Procedure to Remove Non-Endocrine Cells
The re-aggregation procedure was optimized for scalability, in order to ensure that the method (unlike previous related techniques34,36-39) may be deployed at scales of several billion cells. SC-islets were dissociated into single cells at the end of Stage 5 differentiation. 300 mL of SC-islets culture were washed in PBS and incubated in 25 mL of TrypLE Express for 20 min at 37° C. Cells were then quenched with DMEM+10% FBS and spun down, before resuspending in 10 mL of Stage 6 culture media. Remaining undissociated cell clusters were mechanically dissociated using a P1000 pipette. The single cell suspension is further diluted to a volume of 50 mL with Stage 6 media, before being passed through a 40 μm mesh filter (pluriSelect) to remove any residual undissociated clusters. The dissociated single cells were counted and seeded into a spinner flask at a density of 1M cells/mL in Stage 6 media and cultured in an incubator at 37° C. with 70 rpm agitation. The endocrine cells self-aggregate into clusters within 24 hours, while progenitor cells remain in the supernatant. After 48 hours of culture, cells were fed by spinning down all the cells and resuspending in fresh Stage 6 media. Subsequent media changes were done every 48 hours using a 20 μm mesh filter (pluriSelect). The re-aggregated clusters enriched with endocrine cells were collected on the 20 μm mesh filter and reseeded back in the spinner flask with Stage 6 media at the original volume. Supernatant containing single cells that passed through the 20 μm mesh filter were discarded.
Magnetic Enrichment Using CD49a/ITGA1
Stage 6 clusters (taken at Stage 6 week 2) were dissociated as in the re-aggregation section above, starting with 75 mL of Stage 6 culture. The dissociated single-cells were resuspended in sorting buffer (PBS+1% BSA+2 mM EDTA) and filtered through a 35 μm mesh filter. Cells were counted and resuspended at a density of 10M cells per 300 μL in 15 mL conical tubes. Cells were stained at room temp for 20 minutes using a 1:100 dilution of Anti-human CD49a PE-conjugated (BD #559596) antibody, covered from light and agitated every 3 minutes. Stained cells were washed twice with 15 mL of sorting buffer by spinning down (5 min, 300 g) and resuspending to their initial density of 10M cells per 300 μL. To label with microbeads, 40 μL of anti-PE UltraPure MACS microbreads (Miltenyi 130-105-639) were added for each 10M cells and the cell solution was incubated for 15 minutes at 4° C., agitated every 5 minutes. The stained cells were washed twice as above and resuspended to a target density of 25M-30M cells per 500 μL. Volumes of 500 μL (containing no more than 30M cells) were then magnetically separated on LS columns (Miltenyi 130-042-401) in a QuadroMACS separator (Miltenyi 130-090-976) using the recommend protocol. Briefly, 500 μL of cells were added to a pre-washed column, washed with 3 mL of sorting buffer three times, removed from the separator and washed with a final volume of 5 mL. The final cell fraction from different columns were pooled. Successful PE enrichment was verified by live cell flow cytometry on a Attune NxT (Invitrogen) flow cytometer, showing enrichment of 70%+ in a typical experiment. An example purification result is shown in
Preparation of Differentiated Cells for Sequencing
Differentiated clusters were prepared for single cell RNA sequencing as follows: 1-2 mL suspension culture was sampled from the spinner flask, dissociated with TrypLE Express (5-15 minutes at 37° C.), quenched with cold PBS+1% BSA and gently dispersed with a P1000 pipette. Cells were then centrifuged (300 rpm, 3 min), resuspended in cold PBS+1% BSA and filtered through a 70 μm mesh filter. Centrifugation, resuspension and filtering was repeated a total of 3 times. Cells were then counted and resuspended to the working dilution for inDrops (100,000 cells/mL) in 1×PBS with 13% Optiprep (Sigma; D1556).
inDrops Single Cell RNA Sequencing
Single cell RNA sequencing was carried out using the inDrops platform, as previously described4,40. Most samples were run using ‘inDrops v2’ barcoded hydrogel beads (1 Cell Bio, Harvard Single Cell Core), and one experiment used ‘inDrops v3’ beads (Harvard Single Cell Core). Following the inDrops protocol, each biological sample was split into several aliquots of 1000-3000 cells after encapsulation. At least two library aliquots were prepared separately from each sample, indexed using recommended index sequences, pooled and sequenced on a NextSeq 500 (Illumina). The first set of experiments (Stages 3-6 timecourse) involved sequencing several thousand cells per timepoint and provided an estimate of the expected cell type diversity. For the following Stage 5 and 6 time courses, separate flasks were used as technical replicates and measured thousands of cells from each individual timepoint, increasing the capacity for identifying rare populations or subtle changes in the major cell types.
inDrops Raw Data Processing
Sequencing reads were processed according to the previously published inDrops pipeline (github.com/indrops/indrops/). To run the pipeline, a reference index was built from the Ensembl GRCh38 human genome assembly and the GRCh38.88 transcriptome annotation. Briefly, the pipeline trims reads using Trimmomatic, uses Bowtie 1.1.1 to map reads to the human transcriptome, and quantifies transcript expression counts using the unique molecular identifiers, referred to as UMIFMs. For each library, the UMIFM counts matrix was filtered as follows: genes with less than 3 counts were removed; mitochondrially encoded and under-annotated genes were removed; cells with less than 750 (Stage 5 and 6 time courses) or 1000 (all other datasets) UMIFM counts were removed. Variation in the total counts of each individual cell was removed by normalizing the sum of counts of each cell to 10,000. These normalized counts were used as input below and were converted to TPM values for data presentation.
Dimensionality Reduction and Clustering
Dimensionality reduction and clustering for each dataset was performed by broadly following a modified version of the approach presented in Zeisel et al. 201841. Using the unnormalized counts, highly variable genes were identified as previously described41, by finding outliers with high coefficients of variations as a function of mean expression. Then, within each dataset, (depth normalized) counts values were further z-normalized per gene to yield z-norm values. The z-norm values of variable genes (per dataset) were used as input for principal component analysis (PCA). When computing principal components for the Stage 5 datasets, genes correlated with cell-cycle marker TOP2A (Pearson correlation greater 0.15) were identified and excluded. Clustering was carried out using Leiden community detection42, a recently published improvement on Louvain community detection. For community detection, a mutual kNN graph was created by keeping only the mutual edges of the 250 (Stages 5 and 6 time course) or 100 (other datasets) nearest neighbors of cells in the space of the first 50 PCs. When necessary, community detection was repeated on a subset of the cells to improve the cell annotations. It is noted that keeping only mutual edges improved the ability to resolve SST+/HHEX+ cells, which correspond to cluster the most difficult to correctly distinguish in the data. For each dataset, this dimensionality reduction procedure followed by clustering was carried out twice per dataset. A first pass was used to identify clusters with lower average library sizes, lack of expression markers (as defined using the score in Zeisel et al.) or clear doublet expression patterns. For the Stage 5 and 6 time course, this first pass of filtering was carried out once per time point, and once again for the complete datasets (with the full datasets used thereafter). The filtered cells were ignored in the second pass of clustering. After this second pass of clustering, individual clusters were assigned an identity (and where appropriate, merged with others) by correlating their expression profiles to a set of predefined marker genes for each population. After clusters were interpreted, a scikit-learn random forest classifier of the clusters was trained and used out-of-bootstrap predictions to assign final labels to the cells. This classifier was also used to recover cells removed in the first pass filter, by retaining cells whose predicted label had a 66% majority across random trees, recovering approximately ˜5% of the cells across datasets. These retained cells were incorporated in downstream analyses but ignored when finding principal components. tSNE projections were computed with the Python wrapper of the C Barnes-Hut t-SNE implementation (github.com/lvdmaaten/bhtsne), using the first 25 principal components. To compute mean gene expression levels within a label, UMIFM counts were summed for all cells assigned to that label and tpm normalization was computed on these summed counts. The fraction of cells expressing a given gene within a cluster was also computed, using 1% of the maximal expression of that gene (in any cell of the same dataset) as a threshold for qualifying as expressed. The correlation of groups of cells (as in
Diffusion Pseudotime Analysis
Diffusion pseudotime analysis (DPT)43 was performed using the Scanpy package44, using 100 nearest-neighbors in 10 unscaled principal components to find 10 diffusion components. The DPT was then computed from a manually specified root cell and cells were ordered by their rank along DPT branches (if any). In the Stage 5 branching analysis, cells assigned to the SC-beta or SC-EC clusters were assigned to that branch, while progenitor cells were randomly assigned to a branch. Pseudotime along each branch scales from 0 to 1 corresponding to ranked ordering of the cells, but adjusting the rank of the progenitors such that both branches diverge from the common progenitors at a value of 0.5. To identify genes whose expression is a function of pseudotime, a version of the BEAM45 model was implemented. For unbranched pseudotime trajectories, two negative binomial generalized linear models are fit using the VGAM R package. The first is a complete model incorporating a natural spline function of pseudotime. The second is a reduced model which does not include the pseudotime spline term. For branched trajectories, a second complete model incorporates the branch term for each cell as a regression variable. Fold-changes between branches, or across the pseudotime trajectories are then computed using the regressed values. Each regression is run on all the cells being analyzed in that specific analysis, the resulting sample sizes for the regressions are: 10,034 (# of SC-beta cells) for the analysis in
Analysis of Human Pancreatic Islet inDrops Data
Raw sequencing reads from Baron et al.5 were reprocessed as described above, to align them the same reference as the in vitro sequencing data. UMIFM counts were converted to tpm for expression analyses as above. Finally, clustering was carried out as described above to identify the same classes of cells as in the original publication.
Re-Analysis of Beta-Cell EED2 Knockout Data
Processed RNA sequencing data was downloaded from GEO (accession number GSE110648). The read count values were used as input to create linear models using Voom47 and Limma48. The original data contains three different genotypes (WT, heterozygous and homozygous EED2-floxed alleles) analyzed at two time points (8 and 25 weeks after induction of knock-out). All conditions have triplicate samples, except the heterozygous and homozygous samples at 25 weeks which have duplicates, for a total of 15 samples. A design-contrast parameterization was used to first define replicate groups across all 6 conditions in the dataset and to subsequently identify genes that are differentially expressed between the 25 weeks post-EED2 KO condition for WT, heterozygous and homozygous EED2-floxed alleles. The Benjamini-Hochberg FDR procedure with alpha=0.05 was used to correct for multiple hypothesis testing.
Re-Analysis of Sorted NKX6.1(GFP)+/− Populations
Complete statistical analyses from Gupta et al.28 were downloaded from the supplementary materials of the publications. The reported mean expression, fold-change and significance values were used directly to generate the relevant figures.
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) was performed using GSEA 3.0 to carry out ‘pre-ranked’ analyses using as input the fold-change between NKX6.1+ progenitors, SC-beta cells and islet beta cells, or the fold-change tracking SC-beta pseudotime expression. The analysis was run including the Hallmark (h.all.v6.2) and Canonical Pathway categories (c2.cp.v6.2) from MSigDB, as well as the custom gene sets defined in
This application claims the benefit of U.S. Provisional Application No. 62/668,242, filed on May 7, 2018. The entire teachings of the above application are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/031221 | 5/7/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62668242 | May 2018 | US |
